Dual-targeted nucleic acid molecule for inhibiting expression of HBV gene and PDL1 gene and use thereof
By designing dual-target nucleic acid molecules containing HBV siRNA and PDL1 siRNA, the hepatitis B virus transcripts are specifically degraded and the PDL1/PD-1 signaling pathway is blocked, solving the problems of low cure rate and immune tolerance in existing HBV treatments, and achieving effective virus clearance and immune function recovery.
Patent Information
- Application Number
- PCT/CN2026/095550
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Existing HBV treatments have low cure rates and are prone to drug resistance, failing to effectively inhibit HBV replication and improve liver disease. Upregulation of PDL1 gene expression leads to immune tolerance, and there are insufficient methods to block the PDL1/PD-1 signaling pathway.
A dual-target nucleic acid molecule containing HBV siRNA and PDL1 siRNA was designed. Through RNAi, it specifically degrades hepatitis B virus transcripts and blocks the PDL1/PD-1 signaling pathway, restores virus-specific T cell function, and inhibits HBV and PDL1 gene expression.
It significantly inhibits the expression of HBV and PDL1 genes, restores immune function, promotes viral clearance, reduces the expression of HBsAg, HBeAg and HBV DNA, and effectively prevents and treats diseases caused by HBV infection.
Smart Images

Figure PCTCN2026095550-FTAPPB-I100001 
Figure PCTCN2026095550-FTAPPB-I100002 
Figure PCTCN2026095550-FTAPPB-I100003
Abstract
Description
A dual-target nucleic acid molecule that inhibits the expression of HBV and PDL1 genes and its applications Technical Field
[0001] This disclosure belongs to the field of biology, specifically relating to a dual-target nucleic acid molecule that inhibits the expression of the HBV gene and the PDL1 gene and its applications. Background Technology
[0002] Hepatitis B virus (HBV) is a strictly hepatotropic virus containing double-stranded DNA. Globally, over 400 million people are chronically infected with HBV and are therefore at increased risk of developing serious liver diseases such as chronic hepatitis, cirrhosis, liver failure, and hepatocellular carcinoma (HCC), resulting in an estimated 600,000 deaths annually. Hepatitis D virus (HDV) (also known as delta virus) is a virus that requires HBV to replicate. HBV-HDV co-infection is the most severe form of chronic viral hepatitis, progressing more rapidly to liver-related death and hepatocellular carcinoma.
[0003] The HBV genome contains four overlapping open reading frames. Targeting the X gene within these frames can effectively inhibit the expression of all four HBV transcripts simultaneously, suppressing the secretion of HBsAg, HBeAg, and HBV DNA. Therefore, targeting the X gene is a potential therapeutic target for HBV. PDL1 is an immune checkpoint molecule, typically expressed by tumor cells or immune cells (such as macrophages and dendritic cells). Its binding to PD-1 on the surface of T cells inhibits T cell activity, helping tumors evade immune surveillance. Furthermore, certain viruses (such as HIV and HBV) can upregulate PDL1 expression in host cells, leading to T cell exhaustion. Inhibiting PDL1 gene expression can block the PDL1 / PD-1 signaling pathway, break immune tolerance, restore virus-specific T cell function, and promote viral clearance.
[0004] The primary goal of HBV treatment is to permanently suppress HBV replication and improve liver disease. Currently, the standard of care for treating chronic HBV infection is daily oral nucleoside analogues or injectable pegylated interferon; however, the cure rate remains low (3-7% for pegylated interferon and 1-12% for nucleoside analogues) and drug resistance is easily developed. Given the significant unmet clinical need for existing anti-HBV treatments, the search for an effective antiviral drug or treatment method is urgently needed. Summary of the Invention
[0005] This disclosure provides a dual-target nucleic acid molecule that inhibits the expression of HBV and PDL1 genes and its application. The dual-target nucleic acid molecule promotes the specific degradation of hepatitis B virus transcripts and blocks the PDL1 / PD-1 signaling pathway through RNAi, thereby relieving immune tolerance, restoring virus-specific T cell function, and promoting virus clearance.
[0006] The first aspect of this disclosure provides a dual-target nucleic acid molecule or a pharmaceutically acceptable salt thereof for inhibiting the expression of the HBV gene and the PDL1 gene, comprising, via a linker, an HBV siRNA for inhibiting HBV gene expression and a PDL1 siRNA for inhibiting PDL1 gene expression, wherein the HBV siRNA comprises a sense strand and an antisense strand that complementarily form a double-stranded region, or is composed of a sense strand and an antisense strand that complementarily form a double-stranded region; and the PDL1 siRNA comprises a sense strand and an antisense strand that complementarily form a double-stranded region, or is composed of a sense strand and an antisense strand that complementarily form a double-stranded region; optionally:
[0007] The antisense strand of the PDL1 siRNA has a nucleotide length of 18-23 nt, and the antisense strand comprises or is a sequence of 18-21 consecutive nucleotides, which are no more than 3 nucleotides distinct from the first to the 21st nucleotides starting from the 5' end of any one of the sequences SEQ ID NO: 58, 18, 24, 114, 140.
[0008] In some embodiments, the antisense strand of the HBV siRNA has a nucleotide length of 18-23 nt and comprises or is a continuous nucleotide sequence of 18-21 nucleotides, consisting of no more than 3 nucleotides distinguishable from the first to 21 nucleotides from the 5' end of any one of the sequences SEQ ID NO: 2, 4, 6, or 8.
[0009] In some embodiments, the difference of no more than three nucleotides in the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt may be a difference of three nucleotides, a difference of two nucleotides, a difference of one nucleotide, or complete sameness.
[0010] In some embodiments, the 18-21 consecutive nucleotide sequences of the aforementioned dual-target nucleic acid molecules or their pharmaceutically acceptable salts are 18, 19, 20, or 21 consecutive nucleotide sequences.
[0011] In some embodiments, the lengths of the double-stranded regions of the aforementioned dual-target nucleic acid molecules or their pharmaceutically acceptable salts are independently 18-23 bp, optionally 18-21 bp, or 20-21 bp.
[0012] In some embodiments, the antisense strand of the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt comprises 20 consecutive nucleotide sequences from the 2nd to 21st positions of any one of the sequences SEQ ID NO: 58, 18, 24, 114, 140, with the nucleotide from the 5' end being any one of A, U, G, and C, optionally A or U.
[0013] In some embodiments, the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt may further include 1-6 overhanging nucleotides at its 3' and / or 5' ends of the PDL1 siRNA sense strand and / or PDL1 siRNA antisense strand; optionally, the overhangs may be 2-6 nucleotides, 1-5 nucleotides, 2-5 nucleotides, 1-4 nucleotides, 2-4 nucleotides, 1-3 nucleotides, 2-3 nucleotides, 1-2 nucleotides, or 2 nucleotides.
[0014] In some embodiments, the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt may further include 1-6 overhanging nucleotides at its 3' and / or 5' ends. Optionally, the overhangs may be 2-6 nucleotides, 1-5 nucleotides, 2-5 nucleotides, 1-4 nucleotides, 2-4 nucleotides, 1-3 nucleotides, 2-3 nucleotides, 1-2 nucleotides, or 2 nucleotides.
[0015] In some embodiments, the PDL1 siRNA antisense strand is a polynucleotide sequence as shown in any one of SEQ ID NO: 58, 18, 24, 114, 140 or a polynucleotide sequence as shown in positions 1-21 of any one of SEQ ID NO: 58, 18, 24, 114, 140.
[0016] In some embodiments, the above-mentioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt may have an HBV siRNA antisense strand that is a polynucleotide sequence as shown in SEQ ID NO: 2, 4, 6 or 8, or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 2, 4, 6 or 8.
[0017] In some embodiments, the aforementioned dual-target nucleic acid molecules or their pharmaceutically acceptable salts, wherein: in the PDL1 siRNA,
[0018] The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 57, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 58 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 58;
[0019] The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 17, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 18 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 18;
[0020] The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 23, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 24 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 24;
[0021] The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 113, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 114 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 114;
[0022] Alternatively, the sense strand may be a polynucleotide sequence as shown in SEQ ID NO: 139, and the antisense strand may be a polynucleotide sequence as shown in SEQ ID NO: 140 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 140.
[0023] In some embodiments, the aforementioned dual-target nucleic acid molecules or their pharmaceutically acceptable salts, wherein: in HBV siRNA,
[0024] The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 1, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 2 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 2;
[0025] The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 3, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 4 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 4;
[0026] The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 5, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 6 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 6;
[0027] Alternatively, the sense strand may be a polynucleotide sequence as shown in SEQ ID NO: 7, and the antisense strand may be a polynucleotide sequence as shown in SEQ ID NO: 8 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 8.
[0028] In some embodiments, the HBV siRNA and PDL1 siRNA have a nucleotide length difference of more than 2 nucleotides (e.g., 2 nucleotides, 3 nucleotides) between their sense and antisense strands.
[0029] In some embodiments, the antisense strand of the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt is 23 nt long, and the antisense strand of the PDL1 siRNA is 21 nt long; further optionally, the sense strand of the HBV siRNA is 21 nt long, and the sense strand of the PDL1 siRNA is 21 nt long; even more optionally, the 2 nt extension of the antisense strand of the HBV siRNA compared to the sense strand is located at the 3' end of the HBV siRNA antisense strand.
[0030] In some implementation methods, the aforementioned dual-target nucleic acid molecules or their pharmaceutically acceptable salts may be used.
[0031] The sequence of the HBV siRNA sense strand is the nucleotide sequence shown in SEQ ID NO: 3, and the sequence of the HBV siRNA antisense strand is the nucleotide sequence shown in SEQ ID NO: 4.
[0032] The sequence of the PDL1 siRNA sense strand is the nucleotide sequence shown in SEQ ID NO: 57, and the sequence of the PDL1 siRNA antisense strand is the nucleotide sequence shown in positions 1-21 of SEQ ID NO: 58.
[0033] The above-mentioned dual-target nucleic acid molecules or their pharmaceutically acceptable salts, wherein the motifs of the positive strand of the PDL 1 siRNA and the positive strand of the HBV siRNA independently contain the following modifications: 2'-fluorination of the 7th and 9th-12th nucleosides of the positive strand starting from the 5' end, and 2'-O-methylation of the remaining nucleosides of the positive strand.
[0034] In some embodiments, the aforementioned dual-target nucleic acid molecules or their pharmaceutically acceptable salts have 2'-fluoro modifications at the 7th and 9th-12th nucleoside positions, starting from the 5' end, of both the PDL1 siRNA and HBV siRNA sense strands, and the remaining nucleoside 2' positions of the sense strand have 2'-O-methyl modifications. In this limitation, the 2' positions of each nucleoside have only the corresponding modifications described above, but modifications at other nucleoside positions are not limited.
[0035] In some embodiments, the aforementioned dual-target nucleic acid molecules or their pharmaceutically acceptable salts have 2'-fluoronucleotides at positions 7 and 9-12, independently of each other, starting from the 5' end of the PDL1 siRNA and HBV siRNA sense strands, and the remaining nucleotides of the sense strand are 2'-O-methylnucleotides. In these embodiments, the nucleotides are the corresponding nucleosides; for example, the 2'-fluoronucleotides can be 2'-fluoroguanosine or 2'-fluorocytidine. That is, compared to natural nucleosides, each nucleoside only has the corresponding modifications described above, which is equivalent to limiting the positions of the nucleosides other than the 2' position. In these embodiments, there are no special limitations on the phosphate ester bonds connecting the various nucleosides; they can be ordinary phosphate ester bonds or other modified phosphate ester bonds, such as thiophosphate bonds.
[0036] In some embodiments, the motifs of the aforementioned dual-target nucleic acid molecules or their pharmaceutically acceptable salts include, independently, the following modifications: 2'-fluoro modification of the nucleosides at positions 2, 14, and 16 of the antisense strand starting from the 5' end, and 2'-O-methyl modification of the remaining nucleosides of the antisense strand.
[0037] In some embodiments, the aforementioned dual-target nucleic acid molecules or their pharmaceutically acceptable salts have 2'-fluorinated nucleotides at positions 2, 14, and 16, starting from the 5' end, on both the PDL1 siRNA and HBV siRNA antisense strands, while the remaining nucleotides on the antisense strand have 2'-O-methyl modifications at their 2' positions. In these embodiments, the 2' positions of each nucleotide are only modified as described above, but modifications at other nucleotide positions are not limited.
[0038] In some embodiments, the aforementioned dual-target nucleic acid molecules or their pharmaceutically acceptable salts have 2'-fluoronucleosides at positions 2, 14, and 16, starting from the 5' end, and 2'-O-methyl-5'-vinylphosphonate-nucleoside, respectively, and the remaining nucleosides of the antisense strand are 2'-O-methyl modified. In these embodiments, the nucleosides are the corresponding nucleosides; for example, the 2'-fluoronucleosides can be 2'-fluoroguanosine or 2'-fluorocytidine. That is, compared to natural nucleosides, each nucleoside only has the corresponding modifications described above, which is equivalent to limiting the nucleosides to positions other than the 2' position. In these embodiments, there is no particular limitation on the phosphate ester bonds connecting the various nucleosides; they can be ordinary phosphate ester bonds or other modified phosphate ester bonds, such as thiophosphate bonds.
[0039] In some embodiments, the motif combination of the positive and negative strands of the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt, and the motif combination of the positive and negative strands of the PDL1 siRNA, independently include the following modifications: 2'-fluorination of the 7th and 9th-12th nucleosides of the positive strand starting from the 5' end, and 2'-O-methylation of the remaining nucleosides of the positive strand; 2'-fluorination of the 2nd, 14th, and 16th nucleosides of the antisense strand starting from the 5' end, and 2'-O-methylation of the remaining nucleosides of the antisense strand.
[0040] In some embodiments, the motif combination of the positive and negative strands of the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt, and the motif combination of the positive and negative strands of the HBV siRNA, independently include the following modifications: the 2' positions of the 7th and 9th-12th nucleosides starting from the 5' end of the positive strand are 2'-fluorinated, and the 2' positions of the remaining nucleosides of the positive strand are 2'-O-methyl; the 2' positions of the 2nd, 14th, and 16th nucleosides starting from the 5' end of the antisense strand are 2'-fluorinated, and the 2' positions of the remaining nucleosides of the antisense strand are 2'-O-methyl.
[0041] In some embodiments, the motif combination of the positive and negative strands of the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt, and the motif combination of the positive and negative strands of the PDL1 siRNA, independently include the following modifications: the nucleotides at positions 7 and 9-12 of the positive strand starting from the 5' end are 2'-fluoronucleosides, and the remaining nucleotides of the positive strand are 2'-O-methylnucleosides; the nucleotides at positions 2, 14, and 16 of the negative strand starting from the 5' end are 2'-fluoronucleosides, the nucleotide at position 1 of the negative strand starting from the 5' end is 2'-O-methyl-5'-vinylphosphonate-nucleoside, and the remaining nucleotides of the negative strand are 2'-O-methyl modified.
[0042] In some embodiments, the linker of the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt links the HBV siRNA and PDL1 siRNA together by linking them to the sense strands of the HBV siRNA and PDL1 siRNA, respectively. The antisense strands of the different siRNA molecules are not directly linked to each other; instead, they become part of the dual-target siRNA molecule by forming a double-stranded region complementary to the corresponding sense strand.
[0043] In some embodiments, the connection direction of the positive strand of HBV siRNA and the positive strand of PDL1 in the above dual-target nucleic acid molecules or their pharmaceutically acceptable salts is as follows: (5')HBV siRNA positive strand (3')-linker-(5')PDL1 siRNA (3').
[0044] In some embodiments, the aforementioned dual-target nucleic acid molecules or their pharmaceutically acceptable salts are linked independently of each other by phosphate thioester bonds between the first to third nucleotides starting from their 5' ends and / or between the first to third nucleotides starting from their 3' ends.
[0045] In some embodiments, the first to third nucleotides of the naked 5' or 3' ends of the above-mentioned dual-target nucleic acid molecules or their pharmaceutically acceptable salts are linked by phosphate thioester bonds.
[0046] In some embodiments, the non-naked 5' or 3' end 1-3 nucleotides of the aforementioned dual-target nucleic acid molecules or their pharmaceutically acceptable salts are linked by phosphate ester bonds.
[0047] In some embodiments, the first to third nucleotides of the non-naked 5' end of the PDL1 siRNA positive strand and the first to third nucleotides of the non-naked 3' end of the HBV siRNA positive strand are linked by phosphate ester bonds; the first to third nucleotides of the naked 3' end of the PDL1 siRNA positive strand, the first to third nucleotides of the naked 5' end of the PDL1 siRNA negative strand, the first to third nucleotides of the naked 3' end of the PDL1 siRNA negative strand, the first to third nucleotides of the naked 5' end of the PDL1 siRNA negative strand, the first to third nucleotides of the naked 5' end of the HBV siRNA positive strand, the first to third nucleotides of the naked 5' end of the HBV siRNA negative strand, and the first to third nucleotides of the naked 3' end of the HBV siRNA negative strand are linked by thiophosphate ester bonds. In this disclosure, a naked 5' or 3' end refers to a nucleotide end in the siRNA chain that is not directly connected to a ligand, linker, or other structure with certain steric hindrance; correspondingly, a non-naked 5' or 3' end refers to a nucleotide end in the siRNA chain that is directly connected to a ligand, linker, or other structure with certain steric hindrance.
[0048] In some embodiments, the above-mentioned dual-target nucleic acid molecules or their pharmaceutically acceptable salts may contain, or be contained in, the HBV siRNA positive strand as shown in SEQ ID NO: 218, the HBV siRNA negative strand as shown in SEQ ID NO: 211, the PDL1 siRNA positive strand as shown in SEQ ID NO: 214, and the PDL1 siRNA negative strand as shown in SEQ ID NO: 215.
[0049] In some embodiments, the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt is conjugated to at least one ligand. In some embodiments, the ligand is selected from the following: cholesterol, biotin, vitamins, galactose derivatives or analogs, lactose derivatives or analogs, N-acetylgalactosamine derivatives or analogs, and N-acetylglucosamine derivatives or analogs.
[0050] In some embodiments, the ligand in the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt is an organ-targeting ligand. In some embodiments, the ligand in the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt is a liver-targeting ligand. In some embodiments, the liver-targeting ligand in the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt is a desialylate glycoprotein receptor (ASGPR) ligand. In some embodiments, the ASGPR ligand in the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt is one or more GalNA c derivatives linked by a divalent or trivalent branched structure. The conjugated ligand can improve the cellular uptake, intracellular targeting, half-life, or drug metabolism or pharmacokinetic properties of nucleic acid molecules. Compared to unconjugated siRNA molecules, ligand-conjugated nucleic acid molecules exhibit enhanced affinity or cellular uptake for selected targets (such as specific tissue types, cell types, organelles, etc.), such as hepatocytes, without interfering with the activity of the nucleic acid molecule.
[0051] In some embodiments, the ligand of the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt is derived from one of the following structures:
[0052] In some embodiments, the ligand in the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt is conjugated to the 3' and / or 5' ends of the HBV siRNA sense strand, the HBV siRNA antisense strand, the PDL1 sense strand, and / or the PDL1 antisense strand of the dual-target nucleic acid molecule. In some embodiments, the ligand in the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt is conjugated as a linker between the 3' end of the HBV siRNA sense strand and the 5' end of the PDL1 siRNA sense strand. In some embodiments, the ligand in the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt is selected from the following structures:
[0053] in This represents a connection to the 3' or 5' end of the positive strand of the nucleic acid molecule.
[0054] In some embodiments, the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt is linked to the 3' or 5' end of the positive strand via a phosphate ester bond or a thiophosphate bond. In some embodiments, the aforementioned dual-target nucleic acid molecule or its pharmaceutically acceptable salt... The 5' position is linked to the 3' end of the HBV siRNA positive strand via a phosphate ester bond, and the 3' position is linked to the 5' end of the PDL1 siRNA positive strand via a phosphate ester bond.
[0055] In some embodiments, the dual-target nucleic acid molecule or its pharmaceutically acceptable salt is selected from the following molecules:
[0056] Wherein: Am, Um, Cm, and Gm represent ribonucleotides A, U, C, and G modified with 2′-O-methyl, respectively; Af, Uf, Cf, and Gf represent ribonucleotides A, U, C, and G modified with 2′-fluoro, respectively; the 's' between adjacent nucleosides indicates that the adjacent nucleosides are linked by a phosphate thioester bond; the 5' position of ligand 2 is linked to the 3' end of the HBV siRNA positive strand by a phosphate ester bond, and the 3' position is linked to the 5' end of the PDL1 siRNA positive strand by a phosphate ester bond. In this disclosure, in the nucleic acid structure represented in sequence form, unless otherwise specified, nucleosides without an 's' are linked by conventional phosphate ester bonds.
[0057] A second aspect of this disclosure also provides a nucleic acid delivery system comprising the aforementioned dual-target nucleic acid molecule or a pharmaceutically acceptable salt thereof.
[0058] In some embodiments, the aforementioned nucleic acid delivery body is a liposome, lipid nanoparticle or other polymer, endosome, exosome or vesicle.
[0059] A third aspect of this disclosure provides a cell comprising the dual-target nucleic acid molecule of the first aspect described above or a pharmaceutically acceptable salt thereof, or comprising a nucleic acid delivery body of the second aspect described above.
[0060] In some embodiments, the cells described above are carrying or transfected with HBV virus. In some embodiments, the cells express HBV virus at a high level.
[0061] In some embodiments, the cells described above are derived from mammalian cells. In some embodiments, the cells include, but are not limited to, primate cells and human cells.
[0062] In some embodiments, the cells described above are derived from, for example, the brain, salivary glands, heart, spleen, lungs, liver, kidneys, intestines, or tumors. In some embodiments, the cells described above are liver cancer cells.
[0063] A fourth aspect of this disclosure provides a pharmaceutical composition comprising: a dual-target nucleic acid molecule of the first aspect or a pharmaceutically acceptable salt thereof, or a nucleic acid delivery body comprising the second aspect, or a cell comprising the third aspect; and a pharmaceutically acceptable excipient.
[0064] The fifth aspect of this disclosure provides the use of the dual-target nucleic acid molecule of the first aspect or a pharmaceutically acceptable salt thereof, the nucleic acid delivery body of the second aspect, the cell of the third aspect, or the pharmaceutical composition of the fourth aspect in the preparation of a medicament.
[0065] In some embodiments of the above-described uses, the drug is a drug that inhibits the expression of the HBV gene and / or PDL1 gene in a subject. In some embodiments of the above-described uses, the drug or the inhibition of HBV gene and / or PDL1 gene expression in a subject is used for the prevention and / or treatment of diseases mediated by HBV virus infection. In some embodiments of the above-described uses, diseases mediated by HBV virus infection include, but are not limited to, chronic hepatitis B (CHB), chronic hepatitis D (CHD), hepatogenic diabetes, cirrhosis, and / or liver cancer.
[0066] In some embodiments of the above-described use, the drug is a drug that inhibits the expression of HBsAg, HBeAg, and HBV DNA of HBV virus. In some embodiments of the above-described use, the level of inhibition of HBsAg, HBeAg, and HBV DNA expression of HBV virus is at least inhibited or reduced by 95%, 90%, 85%, 80%, 75%, 70%, 60%, 50%, 40%, 30%, 20%, or 10%.
[0067] The sixth aspect of this disclosure also provides a method for inhibiting the expression of the HBV gene and / or PDL1 gene in a subject, comprising the following steps:
[0068] Administering an effective dose of the dual-target nucleic acid molecule of the first aspect or a pharmaceutically acceptable salt thereof, the nucleic acid delivery body of the second aspect, the cell of the third aspect, or the pharmaceutical composition of the fourth aspect to a subject who requires inhibition of HBV gene and / or PDL1 gene expression in vivo.
[0069] In some embodiments of the above methods, inhibiting the expression of the HBV gene and / or PDL1 gene in the subject is used for the prevention or treatment of diseases mediated by HBV virus infection. In some embodiments of the above methods, HBV virus infection-mediated diseases include, but are not limited to, human chronic hepatitis B, chronic hepatitis D, hepatogenic diabetes, fatty liver, hyperbilirubinemia, cirrhosis, and / or liver cancer.
[0070] The seventh aspect of this disclosure also provides a dual-target nucleic acid molecule of the first aspect or a pharmaceutically acceptable salt thereof, a nucleic acid delivery body of the second aspect, a cell of the third aspect, or a pharmaceutical composition of the fourth aspect, for the preparation of a drug.
[0071] The eighth aspect of this disclosure also provides a nucleic acid molecule or a pharmaceutically acceptable salt thereof for inhibiting PDL1 gene expression, comprising PDL1 siRNA for inhibiting PDL1 gene expression, said PDL1 siRNA comprising or composed of a sense strand and an antisense strand that complementarily form a double-stranded region, wherein:
[0072] The antisense strand of the PDL1 siRNA has a nucleotide length of 18-23 nt, and the antisense strand comprises or is a sequence of 18-21 consecutive nucleotides, which are no more than 3 nucleotides distinct from the first to the 21st nucleotides starting from the 5' end of any one of the sequences SEQ ID NO: 58, 18, 24, 114, 140.
[0073] In some embodiments, the difference of no more than three nucleotides in the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt may be a difference of three nucleotides, a difference of two nucleotides, a difference of one nucleotide, or complete sameness.
[0074] In some embodiments, the 18-21 consecutive nucleotide sequences of the aforementioned nucleic acid molecules or their pharmaceutically acceptable salts are 18, 19, 20, or 21 consecutive nucleotide sequences.
[0075] In some embodiments, the length of the double-stranded region of the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt is 18-23 bp; alternatively, it is 18-21 bp or 20-21 bp.
[0076] In some embodiments, the antisense strand of the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt comprises 20 consecutive nucleotide sequences from the 2nd to 21st nucleotides starting from the 5' end of any one of the sequences SEQ ID NO: 58, 18, 24, 114, 140, with the 2nd to 21st nucleotides being the first nucleotide starting from the 5' end, which is any one of A, U, G, and C, optionally A or U.
[0077] In some embodiments, the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt may further include 1-6 overhanging nucleotides at its 3' and / or 5' ends. In some embodiments, the overhangs may be 2-6 nucleotides, 1-5 nucleotides, 2-5 nucleotides, 1-4 nucleotides, 2-4 nucleotides, 1-3 nucleotides, 2-3 nucleotides, 1-2 nucleotides, or 2 nucleotides.
[0078] In some embodiments, the PDL1 siRNA antisense strand is a polynucleotide sequence as shown in any one of SEQ ID NO: 58, 18, 24, 114, 140 or a polynucleotide sequence as shown in positions 1-21 of any one of SEQ ID NO: 58, 18, 24, 114, 140.
[0079] In some embodiments, the aforementioned nucleic acid molecules or their pharmaceutically acceptable salts, wherein: in PDL1 siRNA,
[0080] The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 57, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 58 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 58;
[0081] The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 17, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 18 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 18;
[0082] The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 23, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 24 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 24;
[0083] The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 113, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 114 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 114;
[0084] Alternatively, the sense strand may be a polynucleotide sequence as shown in SEQ ID NO: 139, and the antisense strand may be a polynucleotide sequence as shown in SEQ ID NO: 140 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 140.
[0085] In some embodiments, the sequence of the positive strand of the above-mentioned nucleic acid molecule or its pharmaceutically acceptable salt is the nucleotide sequence shown in SEQ ID NO: 57, and the sequence of the negative strand of the PDL1 siRNA is the nucleotide sequence shown in positions 1-21 of SEQ ID NO: 58.
[0086] In some embodiments, the sequence of the positive strand of the PDL1 siRNA is the nucleotide sequence shown in SEQ ID NO: 57, and the sequence of the negative strand of the PDL1 siRNA is the nucleotide sequence shown in SEQ ID NO: 58.
[0087] In some embodiments, the motif of the positive strand of the above-mentioned nucleic acid molecule or its pharmaceutically acceptable salt comprises the following modifications: 2'-fluoro modification of the 7th and 9th-12th nucleosides of the positive strand starting from the 5' end, and 2'-O-methyl modification of the remaining nucleosides of the positive strand.
[0088] In some embodiments, the aforementioned nucleic acid molecules or their pharmaceutically acceptable salts have a 2'-fluorinated nucleotide 2' position at positions 7 and 9-12 of the positive strand of the PDL1 siRNA, starting from the 5' end, and a 2'-O-methyl nucleotide 2' position at the remaining positions of the positive strand. In these embodiments, the 2' positions of each nucleotide have only the corresponding modifications described above, but modifications at other positions of the nucleotides are not limited.
[0089] In some embodiments, the nucleosides at positions 7 and 9-12 of the positive strand of the PDL1 siRNA, starting from the 5' end, are 2'-fluoronucleosides, and the remaining nucleotides of the positive strand are 2'-O-methylnucleosides. In these embodiments, the nucleosides of each nucleotide are the corresponding nucleosides; for example, the 2'-fluoronucleosides can be 2'-fluoroguanosine or 2'-fluorocytidine. That is, compared to natural nucleosides, each nucleoside only has the corresponding modifications described above, which is equivalent to limiting the positions of the nucleosides other than the 2' position. In these embodiments, there are no special limitations on the phosphate ester bonds connecting the various nucleosides; they can be ordinary phosphate ester bonds or other modified phosphate ester bonds, such as thiophosphate bonds.
[0090] In some embodiments, the motif of the PDL1 siRNA antisense strand comprises the following modifications: 2'-fluoro modification of the nucleosides at positions 2, 14, and 16 of the antisense strand starting from the 5' end, and 2'-O-methyl modification of the remaining nucleosides of the antisense strand.
[0091] In some embodiments, the 2' positions of the aforementioned nucleic acid molecules or their pharmaceutically acceptable salts in the PDL1 siRNA antisense strand, starting from the 5' end, are 2'-fluorinated at positions 2, 14, and 16, and the remaining 2' positions of the nucleosides in the antisense strand are 2'-O-methylated. In these embodiments, the 2' positions of each nucleoside only have the corresponding modifications described above, but modifications at other positions of the nucleosides are not limited.
[0092] In some embodiments, the nucleosides at positions 2, 14, and 16 of the PDL1 siRNA antisense strand, starting from the 5' end, are 2'-fluoronucleosides, and the nucleoside at position 1, starting from the 5' end, is 2'-O-methyl-5'-vinylphosphonate-nucleoside. The remaining nucleosides of the antisense strand are 2'-O-methyl modified. In these embodiments, the nucleosides are the corresponding nucleosides; for example, the 2'-fluoronucleosides can be 2'-fluoroguanosine or 2'-fluorocytidine. That is, compared to the natural nucleosides, each nucleoside only has the corresponding modifications described above, which is equivalent to limiting the positions of the nucleosides other than the 2' position. In these embodiments, there is no particular limitation on the phosphate ester bonds connecting the various nucleosides; they can be ordinary phosphate ester bonds or other modified phosphate ester bonds, such as thiophosphate bonds.
[0093] In some embodiments, the motif combination of the sense strand motif and the antisense strand motif of the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt comprises the following modifications: 2'-fluorination of the 7th and 9th-12th nucleosides of the sense strand starting from the 5' end, and 2'-O-methylation of the remaining nucleosides of the sense strand; 2'-fluorination of the 2nd, 14th, and 16th nucleosides of the antisense strand starting from the 5' end, and 2'-O-methylation of the remaining nucleosides of the antisense strand.
[0094] In some embodiments, the motif combination of the sense strand motif and the antisense strand motif of the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt comprises the following modifications: the 2' positions of the 7th and 9th-12th nucleosides starting from the 5' end of the sense strand are 2'-fluorinated, and the 2' positions of the remaining nucleosides of the sense strand are 2'-O-methyl; the 2' positions of the 2nd, 14th, and 16th nucleosides starting from the 5' end of the antisense strand are 2'-fluorinated, and the 2' positions of the remaining nucleosides of the antisense strand are 2'-O-methyl.
[0095] In some embodiments, the motif combination of the sense strand motif and the antisense strand motif of the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt comprises the following modifications: the nucleotides at positions 7 and 9-12 of the sense strand starting from the 5' end are 2'-fluoronucleotides, and the remaining nucleotides of the sense strand are 2'-O-methylnucleotides; the nucleotides at positions 2, 14, and 16 of the antisense strand starting from the 5' end are 2'-fluoronucleotides, the nucleotide at position 1 of the antisense strand starting from the 5' end is 2'-O-methyl-5'-vinylphosphonate-nucleoside, and the remaining nucleotides of the antisense strand are 2'-O-methyl modified.
[0096] In some embodiments, the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt is linked by a phosphate thioester bond between the first 1-3 nucleotides of the PDL1 siRNA sense strand and the PDL1 siRNA antisense strand, which are independently linked from their respective 5' ends and / or from their respective 3' ends.
[0097] In some embodiments, the first to third nucleotides of the naked 5' or 3' ends of the above-mentioned nucleic acid molecules or their pharmaceutically acceptable salts are linked by phosphate thioester bonds between the naked 5' or 3' ends of the PDL1 siRNA sense strand and / or the PDL1 siRNA antisense strand.
[0098] In some embodiments, the first to third nucleotides of the non-naked 3' end of the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt are linked by a phosphate thioester bond; the first to third nucleotides of the naked 5' end of the PDL1 siRNA positive strand, the first to third nucleotides of the naked 5' end of the PDL1 siRNA negative strand, and the first to third nucleotides of the naked 3' end of the PDL1 siRNA negative strand are linked by a phosphate ester bond. In this disclosure, a naked 5' end or 3' end refers to a nucleotide terminus in the siRNA chain that is not directly linked to a ligand, linker, or other sterically hindered structure; correspondingly, a non-naked 5' end or 3' end refers to a nucleotide terminus in the siRNA chain that is directly linked to a ligand, linker, or other sterically hindered structure.
[0099] In some embodiments, the above-mentioned nucleic acid molecule or its pharmaceutically acceptable salt may contain, or be a nucleotide sequence as shown in SEQ ID NO: 216, and the PDL1 siRNA antisense strand may contain, or be a nucleotide sequence as shown in SEQ ID NO: 217.
[0100] In some embodiments, the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt is conjugated to at least one ligand. In some embodiments, the ligand is selected from the following: cholesterol, biotin, vitamins, galactose derivatives or analogs, lactose derivatives or analogs, N-acetylgalactosamine derivatives or analogs, and N-acetylglucosamine derivatives or analogs.
[0101] In some embodiments, the ligand in the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt is an organ-targeting ligand. In some embodiments, the ligand in the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt is a liver-targeting ligand. In some embodiments, the liver-targeting ligand in the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt is a desialylate glycoprotein receptor (ASGPR) ligand. In some embodiments, the ASGPR ligand in the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt is one or more Ga1NAc derivatives linked by a divalent or trivalent branched structure. The conjugated ligand can improve the cellular uptake, intracellular targeting, half-life, or drug metabolism or pharmacokinetic properties of nucleic acid molecules; compared to unconjugated siRNA molecules, ligand-conjugated nucleic acid molecules have enhanced affinity or cellular uptake for selected targets (such as specific tissue types, cell types, organelles, etc.), such as hepatocytes, and ligand conjugation does not interfere with the activity of the nucleic acid molecule.
[0102] In some implementation methods, the aforementioned nucleic acid molecules or their pharmaceutically acceptable salts may be used. It is conjugated to the 3' end of the positive strand of PDL1 siRNA via a phosphate thioester bond.
[0103] In some embodiments, the nucleic acid molecules described above, or their pharmaceutically acceptable salts, are selected from the following nucleic acid molecules:
[0104] Wherein: Am, Um, Cm, and Gm represent ribonucleotides A, U, C, and G modified with 2′-O-methyl, respectively; Af, Uf, Cf, and Gf represent ribonucleotides A, U, C, and G modified with 2′-fluoro, respectively. The 's' between adjacent nucleotides indicates that the adjacent nucleotides are linked by a phosphate thioester bond, and the 's' at the 3' end of the positive strand indicates that the 3' end of the positive strand is linked to the ligand via a phosphate thioester bond.
[0105] The ninth aspect of this disclosure also provides a nucleic acid delivery system comprising the aforementioned nucleic acid molecule that inhibits PDL1 gene expression or a pharmaceutically acceptable salt thereof.
[0106] In some embodiments, the aforementioned nucleic acid delivery body is a liposome, lipid nanoparticle or other polymer, endosome, exosome or vesicle.
[0107] The tenth aspect of this disclosure provides a cell comprising a nucleic acid molecule or a pharmaceutically acceptable salt thereof that inhibits PDL1 gene expression as described in the eighth aspect, or a nucleic acid delivery body as described in the ninth aspect.
[0108] In some embodiments, the cells described above are carrying or transfected with HBV virus. In some embodiments, the cells express HBV virus at a high level.
[0109] In some embodiments, the cells described above are derived from mammalian cells. In some embodiments, the cells include, but are not limited to, primate cells and human cells.
[0110] In some embodiments, the cells described above are derived from, for example, the brain, salivary glands, heart, spleen, lungs, liver, kidneys, intestines, or tumors. In some embodiments, the cells described above are liver cancer cells.
[0111] The eleventh aspect of this disclosure provides a pharmaceutical composition comprising: a nucleic acid molecule or a pharmaceutically acceptable salt thereof that inhibits PDL1 gene expression as described in the eighth aspect, or a nucleic acid delivery body as described in the ninth aspect, or a cell as described in the tenth aspect; and a pharmaceutically acceptable excipient.
[0112] The twelfth aspect of this disclosure provides the use of a nucleic acid molecule or a pharmaceutically acceptable salt thereof that inhibits PDL1 gene expression as described in the eighth aspect, or a nucleic acid delivery body comprising the ninth aspect, or a cell comprising the tenth aspect, or a pharmaceutical composition comprising the eleventh aspect, in the preparation of a medicament.
[0113] In some embodiments of the above-described uses, the drug is a drug that inhibits the expression of the PDL1 gene in a subject. In some embodiments of the above-described uses, the drug or the inhibition of PDL1 gene expression in a subject is used for the prevention and / or treatment of diseases mediated by HBV virus infection. In some embodiments of the above-described uses, diseases mediated by HBV virus infection include, but are not limited to, chronic hepatitis B (CHB), chronic hepatitis D (CHD), hepatogenic diabetes, cirrhosis, and / or liver cancer.
[0114] In some embodiments of the above-described use, the drug is a drug that inhibits the expression of HBsAg, HBeAg, and HBV DNA of HBV virus. In some embodiments of the above-described use, the level of inhibition of HBsAg, HBeAg, and HBV DNA expression of HBV virus is at least inhibited or reduced by 95%, 90%, 85%, 80%, 75%, 70%, 60%, 50%, 40%, 30%, 20%, or 10%.
[0115] The thirteenth aspect of this disclosure also provides a method for inhibiting PDL1 gene expression in a subject, comprising the following steps:
[0116] The effective dose of the nucleic acid molecule or its pharmaceutically acceptable salt that inhibits PDL1 gene expression as described in the eighth aspect is administered to a subject who requires inhibition of PDL1 gene expression in vivo, or the nucleic acid delivery body comprising the ninth aspect, or the cell comprising the tenth aspect, or the pharmaceutical composition comprising the eleventh aspect.
[0117] In some embodiments of the above methods, inhibiting PDL1 gene expression in a subject is used for the prevention or treatment of diseases mediated by HBV virus infection. In some embodiments of the above methods, HBV virus infection-mediated diseases include, but are not limited to, human chronic hepatitis B, chronic hepatitis D, hepatogenic diabetes, fatty liver, hyperbilirubinemia, cirrhosis, and / or liver cancer.
[0118] The fourteenth aspect of this disclosure also provides a nucleic acid molecule or a pharmaceutically acceptable salt thereof that inhibits PDL1 gene expression as described in the eighth aspect, or a nucleic acid delivery body comprising the ninth aspect, or a cell comprising the tenth aspect, or a pharmaceutical composition comprising the eleventh aspect, for preparing a medicament.
[0119] The fifteenth aspect of this disclosure also provides a nucleic acid molecule or a pharmaceutically acceptable salt thereof for inhibiting HBV gene expression, comprising HBV siRNA for inhibiting HBV gene expression, said HBV siRNA comprising a sense strand and an antisense strand that complementarily form a double-stranded region, or composed of a sense strand and an antisense strand that complementarily form a double-stranded region, wherein:
[0120] The antisense strand of the HBV siRNA has a nucleotide length of 18-23 nt, and the antisense strand comprises or is a continuous nucleotide sequence of 18-21 nucleotides, which are no more than 3 nucleotides distinct from the 1st to 21st nucleotides from the 5' end of the polynucleotide sequence shown in SEQ ID NO: 4 or 6.
[0121] In some embodiments, the difference of no more than three nucleotides in the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt may be a difference of three nucleotides, a difference of two nucleotides, a difference of one nucleotide, or complete sameness.
[0122] In some embodiments, the 18-21 consecutive nucleotide sequences of the aforementioned nucleic acid molecules or their pharmaceutically acceptable salts are 18, 19, 20, or 21 consecutive nucleotide sequences.
[0123] In some embodiments, the nucleotide length of the positive strand of the HBV siRNA is 18-23 nt; alternatively, it is 18-21 nt.
[0124] In some embodiments, the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt may further include 1-6 overhanging nucleotides at its 3' and / or 5' ends. Optionally, the overhangs may be 2-6 nucleotides, 1-5 nucleotides, 2-5 nucleotides, 1-4 nucleotides, 2-4 nucleotides, 1-3 nucleotides, 2-3 nucleotides, 1-2 nucleotides, or 2 nucleotides.
[0125] In some embodiments, the above-mentioned nucleic acid molecule or its pharmaceutically acceptable salt may have an antisense strand of HBV siRNA that is the polynucleotide sequence shown in SEQ ID NO: 4 or 6, or the polynucleotide sequence shown in positions 1-21 of SEQ ID NO: 4 or 6.
[0126] In some embodiments, the aforementioned nucleic acid molecules or their pharmaceutically acceptable salts, wherein: in HBV siRNA,
[0127] The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 3, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 4 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 4;
[0128] Alternatively, the sense strand may be a polynucleotide sequence as shown in SEQ ID NO: 5, and the antisense strand may be a polynucleotide sequence as shown in SEQ ID NO: 6 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 6.
[0129] In some embodiments, the sequence of the positive strand of the HBV siRNA is the nucleotide sequence shown in SEQ ID NO: 3, and the sequence of the negative strand of the HBV siRNA is the nucleotide sequence shown in SEQ ID NO: 4.
[0130] In some embodiments, the motif of the above-mentioned nucleic acid molecule or its pharmaceutically acceptable salt comprises the following modifications: 2'-fluoro modification of the 7th and 9th-12th nucleosides of the positive strand starting from the 5' end of the positive strand, and 2'-O-methyl modification of the remaining nucleosides of the positive strand.
[0131] In some embodiments, the above-mentioned nucleic acid molecules or their pharmaceutically acceptable salts have 2'-fluoro modifications at the 7th and 9th-12th nucleoside positions on the HBV siRNA positive strand starting from the 5' end, and 2'-O-methyl modifications at the remaining nucleoside positions on the positive strand; in this limitation, each nucleoside has only the corresponding modifications described above at its 2' position.
[0132] In some embodiments, the nucleotides at positions 7 and 9-12 of the positive strand of the HBV siRNA, starting from the 5' end, are 2'-fluoronucleotides, and the remaining nucleotides of the positive strand are 2'-O-methylnucleotides. In these embodiments, the nucleotides are the corresponding nucleosides; for example, the 2'-fluoronucleotides can be 2'-fluoroguanosine or 2'-fluorocytidine, meaning that each nucleoside has only the corresponding modifications described above compared to the natural nucleoside. In these embodiments, there are no particular limitations on the phosphate ester bonds connecting the various nucleosides; they can be ordinary phosphate ester bonds or other modified phosphate ester bonds, such as thiophosphate bonds.
[0133] In some embodiments, the motif of the above-mentioned nucleic acid molecule or its pharmaceutically acceptable salt comprises the following modifications: 2'-fluoro modification of the nucleosides at positions 2, 14, and 16 of the antisense strand starting from the 5' end, and 2'-O-methyl modification of the remaining nucleosides of the antisense strand.
[0134] In some embodiments, the motif of the HBV siRNA antisense strand comprises the following modifications: 2'-fluoro modifications are made at the 2' positions of the nucleotides at positions 2, 14, and 16, starting from the 5' end of the HBV siRNA antisense strand; and 2'-O-methyl modifications are made at the 2' positions of the remaining nucleotides of the antisense strand. In these embodiments, the 2' positions of each nucleotide are modified only as described above.
[0135] In some embodiments, the motif of the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt comprises the following modification: the nucleosides at positions 2, 14, and 16 starting from the 5' end of the HBV siRNA antisense strand are 2'-fluoronucleosides, the nucleoside at position 1 starting from the 5' end is 2'-O-methyl-5'-vinylphosphonate-nucleoside, and the remaining nucleosides of the antisense strand are 2'-O-methyl modified. In these embodiments, the nucleosides of each nucleotide are the corresponding nucleosides, such as 2'-fluoronucleosides which can be 2'-fluoroguanosine or 2'-fluorocytidine, i.e., each nucleoside has only the corresponding modifications described above compared to the natural nucleosides. In these embodiments, the phosphate ester bonds connecting the various nucleosides are not specifically limited in this specification; they can be ordinary phosphate ester bonds or other modified phosphate ester bonds, such as thiophosphate bonds.
[0136] In some embodiments, the motif combination of the sense strand motif and the antisense strand motif of the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt comprises the following modifications: 2'-fluorination of the 7th and 9th-12th nucleosides of the sense strand starting from the 5' end, and 2'-O-methylation of the remaining nucleosides of the sense strand; 2'-fluorination of the 2nd, 14th, and 16th nucleosides of the antisense strand starting from the 5' end, and 2'-O-methylation of the remaining nucleosides of the antisense strand.
[0137] In some embodiments, the motif combination of the sense strand motif and the antisense strand motif of the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt comprises the following modifications: the 2' positions of the 7th and 9th-12th nucleosides starting from the 5' end of the sense strand are 2'-fluorinated, and the 2' positions of the remaining nucleosides of the sense strand are 2'-O-methyl; the 2' positions of the 2nd, 14th, and 16th nucleosides starting from the 5' end of the antisense strand are 2'-fluorinated, and the 2' positions of the remaining nucleosides of the antisense strand are 2'-O-methyl.
[0138] In some embodiments, the motif combination of the sense strand motif and the antisense strand motif of the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt comprises the following modifications: the 7th and 9th-12th nucleosides of the sense strand starting from the 5' end are 2'-fluoronucleosides, and the remaining nucleotides of the sense strand are 2'-O-methylnucleosides; the 2nd, 14th, and 16th nucleosides of the antisense strand starting from the 5' end are 2'-fluoronucleosides, the 1st nucleoside of the antisense strand starting from the 5' end is 2'-O-methyl-5'-vinylphosphonate-nucleoside, and the remaining nucleosides of the antisense strand are 2'-O-methyl modified.
[0139] In some embodiments, the phosphate ester bonds between the HBV siRNA sense strand and the HBV siRNA antisense strand, starting independently from their respective 5' ends and / or from their respective 3' ends, are thiomodified, meaning that these nucleotides are linked by thiophosphate bonds.
[0140] In some embodiments, the phosphate ester bonds between the first to third nucleotides at the naked 5' or 3' ends of the above-mentioned nucleic acid molecules or their pharmaceutically acceptable salts are thiolated; that is, these nucleotides are linked by thiophosphate bonds.
[0141] In some embodiments, the phosphate ester bonds between the first to third nucleotides of the non-naked 3' end of the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt are thiolated, meaning these nucleotides are linked by thiophosphate bonds; the first to third nucleotides of the naked 5' end of the HBV siRNA positive strand, the first to third nucleotides of the naked 5' end of the HBV siRNA negative strand, and the first to third nucleotides of the naked 3' end of the HBV siRNA negative strand are linked by phosphate esters. In this disclosure, the naked 5' end or 3' end refers to the nucleotide end of the siRNA chain that is not directly linked to a ligand, linker, or other sterically hindered structure; correspondingly, the non-naked 5' end or 3' end refers to the nucleotide end of the siRNA chain that is directly linked to a ligand, linker, or other sterically hindered structure.
[0142] In some embodiments, the above-mentioned nucleic acid molecule or its pharmaceutically acceptable salt may contain, or be a nucleotide sequence as shown in SEQ ID NO: 209, and the HBV siRNA antisense strand may contain, or be a nucleotide sequence as shown in SEQ ID NO: 210.
[0143] In some embodiments, the above-mentioned nucleic acid molecule or its pharmaceutically acceptable salt may contain, or be a nucleotide sequence as shown in SEQ ID NO: 209, and the HBV siRNA antisense strand may contain, or be a nucleotide sequence as shown in SEQ ID NO: 211.
[0144] In some embodiments, the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt is conjugated with at least one ligand. In some embodiments, the ligand is selected from the following: cholesterol, biotin, vitamins, galactose derivatives or analogs, lactose derivatives or analogs, N-acetylgalactosamine derivatives or analogs, and N-acetylglucosamine derivatives or analogs.
[0145] In some embodiments, the ligand in the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt is an organ-targeting ligand. In some embodiments, the ligand in the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt is a liver-targeting ligand. In some embodiments, the liver-targeting ligand in the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt is a desialylate glycoprotein receptor (ASGPR) ligand. In some embodiments, the ASGPR ligand in the aforementioned nucleic acid molecule or its pharmaceutically acceptable salt is one or more GalNAc derivatives linked via a divalent or trivalent branched structure. The conjugated ligand can improve the cellular uptake, intracellular targeting, half-life, or drug metabolism or pharmacokinetic properties of nucleic acid molecules; compared to unconjugated siRNA molecules, ligand-conjugated nucleic acid molecules exhibit enhanced affinity or cellular uptake for selected targets (such as specific tissue types, cell types, organelles, etc.), such as hepatocytes, and ligand conjugation does not interfere with the activity of the nucleic acid molecule.
[0146] In some implementation methods, the aforementioned nucleic acid molecules or their pharmaceutically acceptable salts may be used. It is conjugated to the 3' end of the positive strand of HBV siRNA via a thiophosphate bond.
[0147] In some embodiments, the nucleic acid molecules described above are selected from the following nucleic acid molecules:
[0148] Wherein: Am, Um, Cm, and Gm represent ribonucleotides A, U, C, and G modified with 2′-O-methyl, respectively; Af, Uf, Cf, and Gf represent ribonucleotides A, U, C, and G modified with 2′-fluoro, respectively. The 's' between adjacent nucleotides indicates that the adjacent nucleotides are linked by a phosphate thioester bond, and the 's' at the 3' end of the positive strand indicates that the 3' end of the positive strand is linked to the ligand via a phosphate thioester bond.
[0149] The sixteenth aspect of this disclosure also provides a nucleic acid delivery system comprising the aforementioned nucleic acid molecule that inhibits HBV gene expression or a pharmaceutically acceptable salt thereof.
[0150] In some embodiments, the aforementioned nucleic acid delivery body is a liposome, lipid nanoparticle or other polymer, endosome, exosome or vesicle.
[0151] The seventeenth aspect of this disclosure provides a cell comprising a nucleic acid molecule or a pharmaceutically acceptable salt thereof that inhibits HBV gene expression as described in the fifteenth aspect, or a nucleic acid delivery body as described in the sixteenth aspect.
[0152] In some embodiments, the cells described above are carrying or transfected with HBV virus. In some embodiments, the cells express HBV virus at a high level.
[0153] In some embodiments, the cells described above are derived from mammalian cells. In some embodiments, the cells include, but are not limited to, primate cells and human cells.
[0154] In some embodiments, the cells described above are derived from the brain, salivary glands, heart, spleen, lungs, liver, kidneys, intestines, or tumors. In some embodiments, the cells described above are liver cancer cells.
[0155] The eighteenth aspect of this disclosure provides a pharmaceutical composition comprising: a nucleic acid molecule or a pharmaceutically acceptable salt thereof that inhibits HBV gene expression as described in the fifteenth aspect, or a nucleic acid delivery body as described in the sixteenth aspect, or a cell as described in the seventeenth aspect; and a pharmaceutically acceptable excipient.
[0156] The nineteenth aspect of this disclosure provides the use of a nucleic acid molecule or a pharmaceutically acceptable salt thereof that inhibits HBV gene expression as described in the fifteenth aspect, or a nucleic acid delivery body comprising the sixteenth aspect, or a cell comprising the seventeenth aspect, or a pharmaceutical composition comprising the eighteenth aspect, in the preparation of a medicament.
[0157] In some embodiments of the above-described uses, the drug is a drug that inhibits HBV gene expression in a subject. In some embodiments of the above-described uses, inhibiting HBV gene expression in a subject is for the prevention and / or treatment of diseases mediated by HBV virus infection. In some embodiments of the above-described uses, diseases mediated by HBV virus infection include, but are not limited to, chronic hepatitis B (CHB), chronic hepatitis D (CHD), hepatogenic diabetes, cirrhosis, and / or liver cancer.
[0158] In some embodiments of the above-described use, the drug is a drug that inhibits the expression of HBsAg, HBeAg, and HBV DNA of HBV virus. In some embodiments of the above-described use, the level of inhibition of HBsAg, HBeAg, and HBV DNA expression of HBV virus is at least inhibited or reduced by 95%, 90%, 85%, 80%, 75%, 70%, 60%, 50%, 40%, 30%, 20%, or 10%.
[0159] The twentieth aspect of this disclosure also provides a method for inhibiting HBV gene expression in a subject, comprising the following steps:
[0160] Administer to a subject who requires inhibition of HBV gene expression an effective dose of the nucleic acid molecule or a pharmaceutically acceptable salt thereof described in the fifteenth aspect above, or a nucleic acid delivery body described in the sixteenth aspect above, or a cell described in the seventeenth aspect above, or a pharmaceutical composition described in the eighteenth aspect above.
[0161] In some embodiments of the above methods, inhibiting HBV gene expression in the subject is used for the prevention or treatment of diseases mediated by HBV virus infection. In some embodiments of the above methods, HBV virus infection-mediated diseases include, but are not limited to, human chronic hepatitis B, chronic hepatitis D, hepatogenic diabetes, fatty liver, hyperbilirubinemia, cirrhosis, and / or liver cancer.
[0162] The 21st aspect of this disclosure also provides a nucleic acid molecule or a pharmaceutically acceptable salt thereof that inhibits HBV gene expression as described in the 15th aspect, or a nucleic acid delivery body comprising the 16th aspect, or a cell comprising the 17th aspect, or a pharmaceutical composition comprising the 18th aspect, for use in preparing a medicament.
[0163] The twenty-second aspect of this disclosure also provides a nucleic acid molecule composition comprising any of the above-described nucleic acid molecules that inhibit PDL1 gene expression or a pharmaceutically acceptable salt thereof, and a nucleic acid molecule that inhibits HBV gene expression or a pharmaceutically acceptable salt thereof. Attached Figure Description
[0164] Figure 1: In vivo inhibition of HBsAg activity by HBV siRNA and PDL1 siRNA.
[0165] Figure 2: In vivo anti-HBsAg antibody detection results of HBV siRNA and PDL1 siRNA.
[0166] Figure 3: Mouse weight measurement results during HBV siRNA and PDL1 siRNA treatment. Detailed Implementation
[0167] For the purposes of this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural forms, and vice versa. Unless otherwise defined, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by one of ordinary skill in the art to which the described technology pertains. All technical and patent disclosures referenced in this disclosure are incorporated herein by reference in their entirety.
[0168] As used in this disclosure, the term "nucleic acid molecule" may refer to any molecule having a nucleotide sequence consisting of two or more nucleotides linked together, the linkage including: linkage via phosphate ester bonds, linkage via modified phosphate ester bonds (e.g., thiophosphate ester bonds), or linkage via other linkage methods.
[0169] As used in this disclosure, the term "nucleotide sequence" refers to a polynucleotide chain composed of nucleotides arranged in a specific sequence, which in this disclosure may constitute a nucleic acid molecule or a segment of a chain of a nucleic acid molecule. Therefore, a "nucleotide sequence" can be represented as a precise polynucleotide sequence composed of various nucleotides (e.g., A, T, C, G, U) (e.g., any one of SEQ ID NO: 1 to 100), or as nucleotides at specific positions within a sequence. Without limitation, a "nucleotide sequence" can be RNA or DNA, or a hybrid molecule of RNA and DNA, and may also incorporate non-natural or artificially modified nucleotides.
[0170] The term "nucleotide" in this disclosure, in addition to referring to naturally occurring ribonucleotide or deoxyribonucleotide monomers, should also be understood to refer to their associated structural variants, including derivatives and analogs, which are functionally equivalent in relation to the specific context in which the nucleotide is used, unless the context explicitly indicates otherwise. For example, "nucleotide" refers to deoxyribonucleotides or ribonucleotides. Nucleotides can be standard nucleotides (i.e., adenosine, guanosine, cytidine, thymidine, and uridine), nucleotide isomers, or nucleotide analogs. Nucleotide analogs refer to nucleotides having modified purine or pyrimidine bases or modified ribose moieties. Nucleotide analogs can be naturally occurring nucleotides (e.g., inosine) or non-naturally occurring nucleotides. Non-limiting examples of modifications to the sugar or base moieties of nucleotides include the addition (or removal) of acetyl, amino, carboxyl, carboxymethyl, hydroxyl, methyl, phosphoryl, and thiol groups, as well as the substitution of the carbon and nitrogen atoms of the base by other atoms (e.g., 7-denitropurine). Nucleotide analogs also include dideoxynucleotides, 2′-O-methylnucleotides, locked nucleic acids (LNAs), peptide nucleic acids (PNAs), and morpholino oligonucleotides. In some embodiments, the term "nucleotide" in this disclosure does not include non-natural nucleotides with modified bases. In some embodiments, the term "nucleotide" in this disclosure does not include nucleotides with modified bases. In this disclosure, "G," "C," "A," "T," and "U" generally represent nucleotides with guanine, cytosine, adenine, thymine, and uracil as bases, respectively. However, in the context of RNA and in RNA sequences, unless otherwise specified, "T" refers to uridine or uracil. It should be understood that in the context of nucleotide sequences in this disclosure, unless otherwise specified or contradictory to the context, "nucleotide," "nucleotide residue," and "base" are used interchangeably. The number of nucleotide pairs and base pairs is expressed in bp, where one bp represents one nucleotide pair or one base pair. The number of nucleotides is expressed in nt, where one nt represents one nucleotide. In this disclosure, polynucleotides are DNA or RNA nucleotides, and polynucleotides typically contain an unlimited number of nucleotides. Oligonucleotides are shorter polynucleotides, such as those consisting of 10 to 100 nucleotides.
[0171] As used in this disclosure, the formation of hydrogen bonds between bases or nucleotides according to the Watson-Crick base pairing principle is referred to as complementarity, pairing, or matching, such as A pairing with T or U, C pairing with G or I. All other base pairings are referred to as non-complementarity. When referring to "substantially complementary" between polynucleotide sequences or nucleic acid chains, or between polynucleotide sequences and nucleic acid chains, it means complete complementarity or complementarity of at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%. In complementarity, one or more mismatches are permissible, and one or more bulges are permissible in the polynucleotide sequence or nucleic acid chain; therefore, the resulting complementary regions can be continuous or spaced. If one of the two complementary polynucleotide sequences is shorter than the other, the calculation is based on the number of nucleotides in the shorter sequence. For example, if the sense sequence is 21 nt and the antisense sequence is 23 nt, the length of the complementary region is 21 bp, then it is calculated as 21 / 21, which is 100% complementary, i.e., completely complementary.
[0172] As used in this disclosure, antisense sequence and sense sequence have the common meaning in the art, specifically relative to the target sequences of HBV X gene mRNA and S gene mRNA. That is, an antisense sequence refers to a sequence in the nucleic acid molecule that is substantially complementary to the target gene mRNA sequence, and a sense sequence refers to a sequence in the nucleic acid molecule that has at least 10 consecutive identical nucleotides to the target gene mRNA sequence. In this disclosure, "sense strand" and "sense strand" have the same meaning, corresponding to the antisense strand. Similarly, "sense sequence" and "sense sequence" have the same meaning.
[0173] As used in this disclosure, "siRNA" has the common meaning in the art, comprising two antiparallel and substantially complementary nucleic acid strands. siRNA (small interfering RNA) is a double-stranded RNA that can perform RNAi (RNAi) effects.
[0174] As used in this disclosure, "protruding end" is relative to "flat end" or "flat-ended end," which means that there is no single unpaired nucleotide at the 3' and / or 5' ends of a double-stranded nucleotide; that is, "protruding end" refers to a double-stranded nucleotide in which one strand has more nucleotides than the other strand, resulting in unpaired nucleotides at the 3' and / or 5' ends of the two strands. In this disclosure, "dangling" and "protruding" have the same meaning. In this disclosure, the description of the protruding end of the 5′(s)mN(s)mN3′ structure indicates that the two protruding ribonucleotides at the 3' end are both modified with 2'-O-methyl, and the three ribonucleotides at the 3' end are connected by phosphate thioester bonds.
[0175] As used in this disclosure, the terms "3' end" and "5' end" have the common meaning in the art. Where no specific direction is indicated (i.e., "3' end direction" and "5' end direction"), they encompass the meanings of "3' end" and "5' end," with "3' end" and "5' end" emphasizing the specific end position. In this disclosure, unless it would cause ambiguity to those skilled in the art, no distinction is made between "5' end" and "5' end," nor between "3' end" and "3' end."
[0176] As used in this disclosure, when describing the positions of nucleotides on the same sequence or nucleoside chain, "close," "near," or "far" means the number of nucleotides separating the two nucleotide positions is less or more.
[0177] As used in this disclosure, based on the location of the chemical modification, nucleotide chemical modification methods are classified into phosphate ester modification, base modification, and ribose modification. Chemical modification methods have accelerated the development of siRNA drugs. Due to the uniqueness of drugs, the specific applications of chemical modification methods still need to be explored in different specific scenarios. "Ribose modification" refers to chemical modification at various positions of the sugar ring of ribonucleic acid, including substituent modifications, such as 2'-modification (e.g., 2'-O-methyl, 2'-fluoro, 2'-MOE), 5' modification (e.g., 5'-Mo), and isomer modifications (e.g., LNA, GNA modification). "Phosphate ester" modification mainly refers to modification of the phosphodiester backbone between ribose sugars on siRNA, mainly including thiophosphate (PS), dithiophosphate (PS2), methylphosphate (MP), methoxypropyl phosphate (MOP), and peptide nucleic acid (PNA). Base modification refers to chemical modifications made to the bases of siRNA, mainly divided into three forms: purine modification (such as N6-methyladenosine), pyrimidine modification (such as 5-methylcytidine), and base substitution. When applying specific modifications to a particular siRNA, the impact of modifications at different positions and in different quantities on the overall function of the siRNA needs to be considered. These different overall modification rules are referred to as "motifs" in this disclosure. In the context of motifs in nucleotide sequences, N represents ribonucleotide, dN represents deoxyribonucleotide (DNA), Nm represents 2'-O-Me ribose-modified ribonucleotides or 2'-O-methyl ribonucleotides; Nf represents 2'-F ribose-modified ribonucleotides or 2'-fluororibose-modified ribonucleotides; and s represents a phosphate thioester bond.
[0178] As used in this disclosure, "VP modification" or "5'-vp modification" has the common meaning in the art, referring to a phosphate ester mimicry modification in which a vinyl phosphate ester is linked to the 5' position of a nucleotide, and the structure formed after linkage with the nucleotide is shown below:
[0179] Wherein: Bx1 is a natural or modified base; T2 is a phosphate ester or thiophosphate nucleotide linker that connects the above compound to the oligonucleotide chain; and G is a substituent at the 2' position of the corresponding nucleotide, including but not limited to F, hydroxyl, H, methoxy, methoxyethoxy, etc.
[0180] As used in this disclosure, “GalNAc” or “N-acetylgalactosamine” refers to 2-(acetylamino)-2-deoxy-D-galactopyranose. Unless otherwise specified, the term “GalNAc” or “N-acetylgalactosamine” includes both the β-form and the α-form. Optionally, the GalNAc compounds of this disclosure are in the β-form, namely 2-(acetylamino)-2-deoxy-β-D-galactopyranose. Accordingly, GalNAc derivatives refer to chemical derivatives containing the above-described GalNAc structure.
[0181] The term "solid support" refers to a matrix of inorganic particles, polymers, or other solid materials that can be linked to target compounds by surface modification with active groups (such as NH2), thereby enabling the synthesis of oligonucleotides. Examples of solid supports include, but are not limited to, controllable microporous glass (CPG) and polystyrene (PS).
[0182] The term "conjugate" or "conjugate molecule" refers to a compound formed by the covalent linkage between its individual chemical parts.
[0183] As used in this disclosure, the following abbreviations have the following corresponding meanings:
[0184] “G”, “C”, “A”, “T” and “U” usually represent nucleotides with guanine, cytosine, adenine, thymine and uracil as bases, respectively. GalNAc: N-acetylgalactosamine.
[0185] Abbreviations: N = RNA nucleotide; dN = DNA nucleotide; Nm = 2′-O-methyl modified RNA nucleotide; Nf = 2′-F modified RNA nucleotide; s = adjacent nucleotides are linked by a phosphate thioester bond.
[0186] As used in this disclosure, the term "about" refers to the general range of error for various values that is readily known to those skilled in the art. References to a value or parameter "about" in this disclosure include (and describe) embodiments for that value or parameter itself. As used in this disclosure, when the term "about" precedes a numerical value, it indicates a range of 10% above or below that value. For example, "about 100" encompasses both 90 and 110.
[0187] As used in this disclosure, unless otherwise indicated, the singular forms “a,” “an,” and “the” include the plural forms.
[0188] As used in this disclosure, unless otherwise indicated, the singular forms “a,” “an,” and “the” include the plural forms.
[0189] Note: This is merely a schematic diagram of a thiophosphate diester bond; it also includes the following possible structures: The above structures are interchangeable in this disclosure; This also illustrates a phosphodiester bond, which also includes... The above structures are interchangeable in this disclosure.
[0190] Unless otherwise defined in this disclosure, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains.
[0191] It should be understood that this disclosure includes the various aspects, embodiments, and combinations of said aspects and / or embodiments described herein. The above description and the following embodiments are intended to illustrate, not limit, the scope of this disclosure. Within the scope of the technical concept of this disclosure, various simple modifications can be made to the technical solutions of this disclosure, including combinations of various technical features in any other suitable manner. These simple modifications and combinations should also be considered as part of the content disclosed herein and are all within the protection scope of this disclosure.
[0192] Unless otherwise stated, the practices disclosed herein will employ conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology. All cells are from the Chinese Academy of Sciences Type Culture Collection Committee, or may be from other publicly available sources; other reagents are commercially available.
[0193] It should be understood that this disclosure includes the various aspects, embodiments, and combinations of said aspects and / or embodiments described herein. The above description and the following examples are intended to illustrate, not limit, the scope of this disclosure. Other aspects, improvements, and modifications within the scope of this disclosure will be apparent to those skilled in the art to which this disclosure pertains. Therefore, those skilled in the art should recognize that the scope of this disclosure also includes the improvements and modifications to the said aspects and embodiments.
[0194] Example 1: Screening for HBV-targeting siRNA
[0195] In previous work, the inventors designed siRNAs that target the X gene and cover multiple HBV subtypes. In this disclosure, the siRNAs targeting HBV nucleic acids are selected from the sequences shown in Table 1, wherein molecules 161, 162, 163, and 179 are naked sequence molecules; furthermore, each nucleotide in the above four naked sequence molecules is modified.
[0196] In this embodiment, the single-target naked sequence molecule was modified as follows: (1) Modification on the nucleoside sugar ring: E20 motif modification and E20-VP motif modification (as shown in Table 2); (2) Modification of phosphate bonds between nucleosides: the three nucleotides at the 5' end of the sense strand are linked by thiophosphate bonds, and the three nucleotides at the 3' end of the sense strand are linked by phosphate bonds; the three nucleotides at the 5' end and the three nucleotides at the 3' end of the antisense strand are linked by thiophosphate bonds; (3) Ligand 1 at the 3' end of the sense strand: the 3' end of the sense strand is linked to ligand 1 by thiophosphate bonds.
[0197] E20 modification, combined with modification of the phosphate ester bond between nucleosides and ligand 1 at the 3' end of the positive strand, yielded the corresponding modified molecules GNE161, GNE162, GNE163, and GNE179. Similarly, E20-VP modification, combined with modification of the phosphate ester bond between nucleosides and ligand 1 at the 3' end of the positive strand, yielded the corresponding modified molecules GNVPE161, GNVPE162, GNVPE163, and GNVPE179. The modified sequences of molecules GNE162 and GNVPE162 are illustrated in Table 3. Furthermore, in the screening of HBV siRNAs, the positive control molecule AD66810 was introduced. L96 is linked to the 3' end of the positive strand of the positive control molecule AD66810 via a phosphate ester bond; its sequence and modification details are shown in Table 3.
[0198] Table 1. Naked siRNA sequences targeting the HBv X gene
[0199] Table 2. GN motif modification and GNVP motif modification details
[0200] Table 3. Examples of sequences of molecules GNE162 and GNvPE162, and positive control molecules.
[0201] Note: In the GNE162 and GNVPE162 molecules in this table, the three nucleotides at the 5' end of the sense strand are linked by phosphate thioester bonds, and the three nucleotides at the 3' end of the sense strand are linked by phosphate ester bonds; the three nucleotides at the 5' end and the three nucleotides at the 3' end of the antisense strand are linked by phosphate thioester bonds; ligand 1 is linked to the 3' end of the sense strand by a phosphate thioester bond. L96 is linked to the 3' end of the sense strand by a phosphate ester bond. In this disclosure, nucleotides linked by phosphate ester bonds are not explicitly stated; if linked by phosphate thioester bonds, they will be indicated by 's'.
[0202] 1.1 Screening for in vitro antiviral activity
[0203] The HepG2.2.15 hepatocyte cell line is synthesized by transfecting HepG2 recipient cells with a recombinant plasmid containing the complete HBV-DNA genome. It can proliferate indefinitely in vitro and stably secrete hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and HBV DNA into the culture supernatant. Furthermore, it produces a large number of replication intermediates, making it a standard cell line for in vitro evaluation of HBV drug efficacy. The specific steps for screening the in vitro antiviral efficacy of the synthesized siRNA are as follows:
[0204] HepG2.2.15 cells were cultured in DMEM medium containing 10% fetal bovine serum at 37°C with 5% CO2. When the cells were in the logarithmic growth phase and in good condition (70% confluence), they were seeded and transfected. Cell density was adjusted to 2 × 10⁶ cells per well. 5 Cells were seeded into 24-well plates. The cells were transfected with the chemically modified siRNA as described above. Specific treatment groups and drug administration details are shown in Table 4. Transfection systems with working concentrations of 1 nM, 0.1 nM, and 0.05 nM siRNA were prepared. 250 μL of Opti-MEM and 5 μL of siRNA were mixed, and 250 μL of Opti-MEM and 1.5 μL of RNAiMax transfection reagent were mixed and allowed to stand for 5 min. Then, the two mixtures were combined and allowed to stand for 20 min. The transfection complexes were added to the 24-well plates and incubated at 37°C with 5% CO2 for 6 h. The control group received only the culture medium. The supernatant was aspirated, and 1 mL of complete culture medium (DMEM containing 10% fetal bovine serum) was added to each well. After culturing for 6 days, the cell supernatant was collected for HBsAg, HBeAg, and HBV DNA detection.
[0205] Cell supernatants from each treatment group were collected, and the secretion levels of HBsAg and HBeAg were detected by ELISA, while the secretion of HBV DNA was detected by qPCR. Each treatment group was configured with three replicates, with a Control group serving as a negative control. The inhibition rate for each treatment group was calculated as (Control group content - Treatment group content) / Control group content × 100%. Inhibition rate data were statistically analyzed using GarphPad software, and the results are shown in Table 4.
[0206] Table 4. Screening results of modified siRNAs in HepG2.2.15 cells
[0207] As shown in Table 4, compared with the group without VP modification, the E20-VP motif-modified groups under different drug gradients generally exhibited significantly enhanced antiviral activity. Therefore, molecules modified with the E20-VP motif were used for further validation. Among them, GNVPE161, GNVPE162, and GNVPE163 showed better effects than GNVPE179; compared with AD66810, GNVPE162, GNE163, and GNVPE163 showed higher inhibitory activity against HBsAg, HBeAg, and HBV DNA, especially with a significant advantage in inhibiting HBV DNA activity; therefore, GNVPE162 was mainly selected for further validation.
[0208] 1.2 Validation of in vitro off-target results
[0209] Furthermore, we evaluated the potential off-target effects of various modified siRNA molecules in HepG2.2.15 cells. Transfection systems with working concentrations of 10 nM and 1 nM siRNA were prepared, and the transfection procedure for HepG2.2.15 cells was as described previously. The supernatant was discarded 48 hours after transfection, and cells were harvested 48 hours later. RNA was extracted using the TRIZOL method, and a cDNA library was prepared using the TruSeq Stranded Total RNA Library Prep kit (Illumina). Sequencing was performed on the DNBSEQ platform. Raw RNA-seq reads were filtered using BGI SOAPnuke software, with the following steps: 1) Reads containing adapters (adapter contamination); 2) Reads with an unknown base N content greater than 5% were removed; 3) Low-quality reads were removed (we defined reads with a quality value lower than 15 comprising more than 20% of the total bases in the read as low-quality reads). Finally, HISAT (RNA-seq calibrator) was used to align the filtered reads with the human genome (GCF_000001405.39_GRCh38.p13), and uniquely aligned reads were calculated using featureCounts. Differential gene expression analysis was performed using the R package DESeq2. In this analysis module, the treatment group (siRNA-modified group) was compared with the control group (untreated group). Differentially expressed genes were defined as either |Log2 Fold Change|>=1 and padj (corrected p-value) <0.05 or |Log2 Fold Change|>=1 and padj (corrected p-value) <0.05, and statistical analysis was performed accordingly. Table 5 shows the results of gene-related off-target effects caused by siRNA modification.
[0210] Table 5: Results of gene-related off-target effects caused by siRNA modification
[0211] According to the experimental results in Table 5, compared with the AD66810 reference sequence, the GNVPE161, GNVPE162, GNVPE163, and GNVPE179 developed in this publication have a lower potential off-target risk.
[0212] 1.3 Screening of in vivo efficacy results
[0213] The antiviral efficacy of each siRNA group was further evaluated in mice. Six- to eight-week-old SPF-grade male HBV transgenic Tg (type A, GenBank: AF305422.1) mice (Beijing Viton Technology Co., Ltd.) were randomly assigned to groups of five mice each based on the levels of HBsAg, HBeAg, and HBV DNA measured in blood samples taken on day 3 (D-3) before drug administration. The specific drug administration regimen is shown in Table 6. Blood samples were collected at different time points after drug administration (3 days before administration, 7 days after administration, and 14 days after administration) to measure the levels of HBsAg, HBeAg, and HBV DNA. The statistical results for each group relative to the pre-administration levels are shown in Table 7.
[0214] Table 6. Dosing regimens for HBV Tg mice
[0215] Table 7. Antiviral results in HBV Tg mice
[0216] According to the experimental results in Table 7, when Tg mice were given a single dose of 5 mpk, GNVPE161, GNVPE162, and GNVPE163 showed better inhibition of HBsAg, HBeAg, and HBV DNA than AD66810, with GNVPE162 exhibiting the strongest overall antiviral activity.
[0217] Example 2: Screening of siRNAs targeting the PDL1 gene
[0218] Based on the human PDL1 gene (Gene ID, 29126) mRNA sequence (NM_014143.4), multiple PDL1 siRNA naked sequences were designed at different sites. These siRNA naked sequences were compared with sequence similarity software and showed the lowest homology with all other non-target gene sequences. The PDL1 siRNA naked sequences are shown in Table 8.
[0219] Table 8. List of PDL1 raw sequences
[0220] 2.1 High-throughput screening and detection of PDL1-siRNA in vitro activity
[0221] The high-throughput screening steps for the in vitro activity of siRNAs targeting PDL1 are as follows:
[0222] U87MG cells were cultured in DMEM medium containing 10% fetal bovine serum in a 5% CO2 incubator at 37°C. After cell digestion, the cell density was adjusted to 4 × 10⁶ cells / year. 5 Cells were seeded at a density of 1 ml / well in 12-well plates. A 1 nM siRNA working concentration transfection system was prepared: 45 μL of Opti-MEM and 5 μL of siRNA (naked sequence nucleic acid molecules as shown in Table 8) were mixed, and 48 μL of Opti-MEM and 2 μL of RNAiMax transfection reagent were mixed. The mixture was allowed to stand for 5 min, then the two mixtures were combined and allowed to stand for 20 min to form the transfection complex. This transfection complex was added to the 12-well plates and incubated at 37°C with 5% CO2 for 24 h. Cells were harvested 24 h after transfection and subjected to qPCR detection. The qPCR primer sequences are shown in Table 9. The untreated cell group (Blank) was used as a control for normalization. The residual cell counts of each treatment group relative to the control (Blank) are shown in Table 10.
[0223] Table 9. qPCR primer sequence information
[0224] Table 10: Results of single-dose 10 nM high-throughput screening in U87MG cells
[0225] 2.2 In vitro pharmacodynamic screening results of modified PDL1 siRNA
[0226] We selected some siRNA naked sequence molecules for sequence modification. In this embodiment, the following modifications were performed on the single-target naked sequence molecules: (1) Modification on the nucleoside sugar ring: E20-VP motif modification (as shown in Table 2); (2) Modification of phosphate bonds between nucleosides: the three nucleotides at the 5' end of the sense strand and the three nucleotides at the 3' end are linked by thiophosphate bonds; the three nucleotides at the 5' end of the antisense strand and the three nucleotides at the 3' end are linked by thiophosphate bonds. After E20-VP modification and modification of phosphate bonds between nucleosides, the VPE series molecules modified accordingly in this embodiment were obtained, and no ligands were connected in this part. Taking the VPE25 molecule in this embodiment as an example, the sequence situation after modification is described (as shown in Table 11).
[0227] The modified siRNAs were used to verify their efficacy in U87MG cells at a single dose of 10 nM. Untreated cells served as the control group. The experimental procedures were the same as described in section 2.1. Table 12 shows the screening results of each modified siRNA at a single dose (10 nM) in U87MG cells. The statistical results represent the residual amount of target mRNA in each treatment group relative to the untreated group (defined as 1). The results in Table 12 show that multiple chemically modified siRNA sequences, such as VPE5, VPE8, VPE25, VPE53, and VPE66, exhibited high PDL1 target inhibition rates in vitro.
[0228] Table 11: Examples of VPE25 sequences
[0229] Note: In the molecules in this table, the three nucleotides at the 5' and 3' ends of the sense and antisense strands are all linked by phosphate thioester bonds.
[0230] Table 12: Screening results of single-dose (10 nM) screening of PDL1-modified siRNA in U87MG cells
[0231] 2.3 In vivo efficacy assay of GalNAc-conjugated PDL1 siRNA
[0232] The candidate modified siRNAs VPE5, VPE8, VPE25, VPE53, and VPE66 were further conjugated with ligand 1 to obtain GNVPE5, GNVPE8, GNVPE25, GNVPE53, and GNVPE66. Specifically, GalNAC ligand 1 was conjugated to the 3' end of the siRNA sense sequence via a phosphate thioester. When the ligand is conjugated to the 3' end of the sense strand, the three nucleotides at the 3' end do not need to be linked by a phosphate thioester; they can be linked by a phosphate ester. The synthesized sequence is shown in Table 13, using GNVP25 as an example. We further screened these sequences in mice using the following steps: 6–8 week old SPF-grade PDL1 single-humanized mice (purchased from Biocytogen). On day 0, mice (n=5 per group) were subcutaneously injected with 7.5 mg / kg siRNA or saline. On day 3, all groups were administered 10 mg / kg low molecular weight polyI:C (LMW PIC, from Invivogen) via intravenous injection. Mice were sacrificed 24 hours after LMW PIC administration, and liver tissue was collected. RNA was extracted using the TRIZOL method and detected by qPCR. Table 14 shows the relative content of PDL1 mRNA in each group compared to the saline group.
[0233] Table 13: List of GALNAC-coupled siRNA sequences targeting PDL1
[0234] Table 14 Results of single-dose in vivo efficacy screening of PDL1 siRNA
[0235] As shown in Table 14, the candidate siRNAs modified with ligand 1 exhibited inhibitory activity against the target mRNA exceeding 70% in mice.
[0236] Example 3: Validation of in vivo antiviral activity of HBV siRNA combined with PDL1 siRNA
[0237] We further validated the in vivo antiviral activity of HBV-targeting siRNA combined with PDL1-targeting siRNA. Six- to eight-week-old PD1 / PDL1 dual-humanized mice (Southern Model Organism) were used for modeling. Mice were injected intravenously with subtype C AAV-HBV virus. Six weeks after infection, mice were randomly assigned to groups based on HBsAg levels on day 3 (D-3) before drug administration. The specific drug administration regimen is shown in Table 15. The experiment involved an 8-week drug administration followed by an 8-week observation period. Throughout the experiment, mouse body weight changes were continuously monitored, and anti-HBsAg antibodies were detected during the observation period.
[0238] Table 15: Dosing regimen for AAV-HBV mice
[0239] The results are shown in Figure 1. During the treatment period, GNVPE162 monotherapy significantly downregulated HBsAg levels in mouse serum. On day 49 of the treatment period, the GNVPE162 group achieved complete clearance of HBsAg in mouse serum, with a reduction of -4.27 log. After day 56, during the withdrawal period, the GNVPE162 monotherapy group experienced a rapid rebound in HBsAg levels. Injection of GNVPE25, which targets PDL1, produced sustained antiviral activity, but its inhibitory strength was weaker than that of GNVPE162, with a reduction of -1.9 log in HBsAg levels on day 56. In the combination therapy group, after the last injection, complete clearance of HBsAg in mouse serum was achieved, with a reduction of -4.27 log in HBsAg levels on day 56. After withdrawal, the combination therapy group did not experience a rebound in HBsAg levels during the 8-week observation period, achieving 100% clearance of HBsAg.
[0240] Furthermore, we evaluated the levels of anti-HBsAg antibodies in the serum of mice in each injection group after drug withdrawal in the above experiments. The results are shown in Figure 2 (the horizontal axis represents the total number of days in the experiment). The combination therapy group (n=5 / 5 mice) showed effective serological conversion, with high titers of anti-HBsAg antibodies detectable, demonstrating that the elimination of immune tolerance and immune activation are crucial for maintaining long-term antiviral activity. Although the HBV-targeted siRNA (GNVPE162) significantly inhibited viral activity initially, the inability to elicit an effective immune response (failure to produce corresponding HBsAg antibodies) was the main reason for the rapid rebound, leading to rebound after drug withdrawal. Although antibodies were detectable in a few mice (n=2 / 5 mice) in the PDL1-targeted siRNA (GNVPE25) group, the antibody titers were low. Throughout the experimental period, no significant abnormalities were observed in the body weight of mice in any group (Figure 3).
[0241] Example 4: Validation of the in vivo antiviral activity of dual-target conjugated siRNA
[0242] We tandem HBV-targeting siRNA and PDL1-targeting siRNA using a linker to form a dual-target siRNA. In this embodiment, ligand 2 acts as a linker, connecting the HBV and PDL1 positive strands in the 5'-3' direction of the positive strand, i.e.: (5')HBV positive strand (3')-(5')linker (3')-(5')PDL1 positive strand (3'), thereby linking the HBV siRNA molecule and the PDL1 siRNA molecule. In this embodiment, based on naked sequence molecules, the dual-target siRNA nucleic acid molecules also have the following characteristics: (1) Modification on the nucleoside sugar ring: E20-VP motif modification, wherein; the antisense strand in HBV siRNA is 23nt, and the antisense strand in PDL1 siRNA is 21nt. Although the lengths are different, the motif modification of the shorter PDL1 siRNA antisense strand conforms to the E20-VP motif modification, that is, the modification of the 1-21 nucleosides starting from its 5' end is the same as the modification of the 1-21 nucleosides in the E20-VP motif modification. In this disclosure, the E20-VP (short) motif is used to refer to this motif (as shown in Table 16); (2) Modification of phosphate ester bonds between nucleosides: the three nucleotides at the 3' end of the HBV siRNA sense strand and the three nucleotides at the 5' end of the PDL1 siRNA sense strand are linked by phosphate ester bonds; the three nucleotides at the 5' end of the HBV siRNA sense strand and the PDL1 siRNA sense strand are linked by phosphate ester bonds. The three nucleotides at the 3' end of the siRNA sense strand, the three nucleotides at the 5' end of the HBV siRNA antisense strand, and the three nucleotides at the 3' end of the PDL1 siRNA antisense strand are linked by phosphate thioester bonds; (3) Sense strand ligand 2: The 3' end of the HBV siRNA sense strand is linked to the 5' end of ligand 2 by a phosphate ester bond, and the 5' end of the PDL1 siRNA sense strand is linked to the 3' end of ligand 2 by a phosphate ester bond. Table 17 shows the dual-target nucleic acid molecules in this embodiment.
[0243] Table 16. E20-VP motif modification (long or short)
[0244] Table 17: Molecular structure of dual-target siRNA
[0245] Furthermore, we validated the in vivo antiviral efficacy in an AAV-HBV model. Six- to eight-week-old PD1 / PDL1 dual-humanized mice were used for modeling. Mice were injected with AAV-HBV virus via tail vein. After six weeks of infection, they were injected with BGN13P25 weekly at 10 mpk. Blood samples were collected on days 3 (D-3), 14, and 28 before drug administration to measure the levels of HBsAg, HBeAg, and HBV DNA. The levels of HBsAg, HBeAg, and HBV DNA were log10-logarithmic, and Table 18 shows the statistical results relative to the pre-drug levels.
[0246] Table 18: Results of antiviral activity of dual-target siRNA in mice
[0247] The results show that the dual-target conjugated siRNA still exhibited strong antiviral activity. At day 28, HBsAg decreased by -3.32 log, HBeAg by -1.19 log, and HBV DNA by -2.54 log. No significant abnormalities in mouse body weight were observed during the study. Our research indicates that dual-target siRNA targeting HBV and PDL1 is also an excellent strategy for functional cure of hepatitis B.
[0248] Preparation Example 1: Preparation of phosphoramidite monomers of ligand 1 and ligand 2
[0249] I. Synthesis of Compound 1
[0250] ① Synthesis of compound 16:
[0251] 10 g of compound 15 and 100 mL of pyridine were added to a flask. After stirring to dissolve, the mixture was cooled in an ice bath. 20 g of B2Cl was carefully added dropwise, and the mixture was stirred in an ice bath for 10 min under nitrogen protection. The mixture was then further heated to room temperature and stirred for 16 hours. A saturated aqueous solution of sodium bicarbonate was slowly added to the reaction mixture in an ice bath, and after stirring for 1 hour, the mixture was concentrated to remove pyridine. DCM was added to the residue, and after stirring for 15 min, the mixture was allowed to stand and separated. The organic phase was separated, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was subjected to column chromatography to give 18 g of a white solid powder, with a yield of 85.3%. ESI+MS: m / z 594.3 [M+H] + .
[0252] ② Synthesis of compound 17:
[0253] 10 g of compound 16 and HOAc / Ac2O (50 mL / 50 mL) were added to a flask. After stirring to dissolve, the mixture was heated to 100 °C and stirred at 100 °C for 2 hours. The reaction solution was cooled to room temperature and carefully poured into 200 mL of ice water. DCM was then added, and the mixture was stirred for 15 min. After standing, the liquid was separated, and the organic phase was washed successively with water, 5% sodium bicarbonate aqueous solution, and saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was subjected to column chromatography to give 5 g of white solid powder, with a yield of 71.4%. ESI+MS: m / z 415.2 [M+H] + .
[0254] ③ Synthesis of compound 19:
[0255] 5 g of compound 17 and 40 mL of DCM were added to a three-necked flask. After stirring to dissolve, the mixture was cooled to -30 °C. Under nitrogen protection, 4.02 g of TMSOTf was carefully added dropwise while stirring at -30 °C for 30 min. Subsequently, 3.17 g of a DCM solution of compound 18 was carefully added dropwise. After the addition was complete, stirring was continued at -30 °C for 1 hour. The reaction solution was heated to 0–5 °C, and 5% sodium bicarbonate aqueous solution was carefully added dropwise. After stirring for 15 min, the mixture was allowed to stand and separated. The organic phase was washed successively with 5% sodium bicarbonate aqueous solution and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography and reversed-phase chromatography to obtain 2.8 g of white solid powder, yield 40.5%, ESI+MS: m / z 574.3 [M+H]. + .
[0256] ④ Synthesis of Compound 1:
[0257] 2.5 g of compound 19 and 25 mL of MeOH were added to a flask. The mixture was stirred thoroughly, and 320 mg of MeONa was carefully added dropwise under nitrogen protection. The mixture was stirred at room temperature for 6 hours, followed by concentration. The crude product was then converted to a white solid powder by reverse phase chromatography, yielding 1 g of powder (62.9% yield). ESI-MS: m / z 424.4 [M+OAc] - ] - .
[0258] II. Synthesis of Compound 6
[0259] ① Synthesis of compound 2:
[0260] 1.2 g of compound 1 and 12 mL of pyridine were added to a three-necked flask. After stirring to dissolve, 1.2 g of DMTrCl was added, and the mixture was stirred at room temperature for 1 hour under nitrogen protection. Excess DMTrCl was quenched by slowly adding methanol (0.6 mL) to the reaction mixture, and after stirring at room temperature for 15 min, 303.5 mg of NaHCO3 was added. The mixture was concentrated to obtain a crude product, which was dissolved by adding DCM / H2O and washing with water. The organic phase was dried over anhydrous sodium sulfate and filtered. The collected organic phase was concentrated under vacuum to obtain a crude product of compound 2, which was used directly in the next reaction step.
[0261] ② Synthesis of compound 3:
[0262] Ethanol (24 mL) was added to the crude compound 2, and the temperature was slowly raised to 50 °C. After stirring to dissolve, hydrazine hydrate (0.75 mL) was added, and the mixture was stirred overnight at 50 °C. Then, the temperature was lowered to room temperature, and stirring was continued at room temperature for half an hour. At this point, a large amount of white solid gradually precipitated. The mixture was filtered, and the residue was washed with ethanol. The filtrate was concentrated under reduced pressure, then redissolved in DCM / H2O. The liquid was separated, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The collected organic phase was concentrated under vacuum to obtain the crude compound 3, which was directly used in the next reaction.
[0263] ③ Synthesis of compound 5 (i.e., ligand 1 phosphoridamide monomer):
[0264] 0.9 g of compound 4, 24 mL of DCM, 0.84 mL of Et3N, and 2.3 g of HBTU were added sequentially to the crude compound 3. The mixture was stirred at room temperature for 2 hours under nitrogen protection. The reaction was quenched with 9 mL of water, and the organic phase was separated, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The collected organic phase was concentrated under vacuum and purified by reverse-phase preparation (75% ACN-H2O) to give 1.4 g of compound 5, with a three-step yield of 44.2%. ESI-MS: m / z 1025.6 [M+OAc] - ] - .
[0265] ④ Synthesis of compound 6:
[0266] 1.4 g of compound 5 was dissolved in 14 mL of DCM and cooled at 0 ± 2 °C. 524.7 mg of 2-cyanoethyl-N,N,N′,N′-tetraisopropylphosphonic diamine was added, followed by 81.3 mg of 1H-tetrazole. The reaction mixture was stirred at 0 ± 2 °C for 15 min, then brought to room temperature and stirred for another 2 hours. The reaction mixture was cooled at 0 ± 2 °C, quenched with 14 mL of 5% NaHCO3, and the organic phase was separated. The organic phase was washed with saturated brine (1 x 14 mL) at 0 ± 2 °C, dried over anhydrous sodium sulfate, and filtered. The collected organic phase was concentrated under vacuum, and the crude product was redissolved in DCM / MTBE and carefully added dropwise to a vigorously stirred heptane solution. A large amount of viscous oil gradually precipitated from the walls and bottom of the flask. After standing for 10 min, the supernatant was decanted. The crude product was chromatographically analyzed using EA:hept. = 10:1 to 2:1 as eluent. After concentration and drying, 560 mg of a white solid powder was obtained, with a yield of 32% and a phosphorus spectrum purity of 98.19%. ESI-MS: m / z 1225.4 [M+OAc] - ] - .
[0267] III. Synthesis of Compound 8
[0268] ① Synthesis of compound 7:
[0269] 2g of compound 5 was dissolved in 20mL of DCM, and 248.4mg of succinic anhydride and 0.69mL of Et3N were added sequentially. Finally, 25.3mg of DMAP was added, and the mixture was stirred at room temperature for 16 hours. HPLC monitoring showed a significant amount of reactant remaining, so 310.4mg of succinic anhydride and 0.69mL of Et3N were added. Finally, 25.3mg of DMAP was added, and the mixture was stirred at room temperature for another 36 hours. The reaction solution was cooled at 0±2℃, ice water was added, followed by DCM, and finally 40mL of 1% HOAc aqueous solution was added. After stirring for 10 minutes, the organic phase was separated and washed sequentially with 1% HOAc aqueous solution and water. The organic phase was dried over anhydrous sodium sulfate and filtered. The collected organic phase was concentrated under vacuum to obtain a crude product. The crude product was chromatographically analyzed using DCM:MeOH = 70:1–20:1 eluent. After concentration and drying, 0.9g of white solid powder was obtained, with a yield of 40.7%. No succinic acid residue was detected, and the succinic anhydride residue was 0.26%. ESI-MS: m / z 1065.7 [MH]-.
[0270] ② Synthesis of compound 8 (i.e., monomer of ligand 1 attached to the solid support):
[0271] 300 mg of compound 7, 72.7 mg of DIPEA, 106 mg of HBTU, and 10 mL of acetonitrile were added to a three-necked flask. The mixture was stirred at 25 °C for 10 minutes, followed by the addition of 650 mg of solid support PS. Stirring continued at 25 °C for 24 hours. After the reaction was complete, the mixture was filtered, and the filter cake was washed with acetonitrile. The collected filter cake was concentrated under vacuum to remove the solvent, yielding 850 mg of solid. 700 mg of this solid was added to a three-necked flask, along with 1.74 g of acetic anhydride, 4.15 mg of DMAP, 103 mg of triethylamine, and 10 mL of pyridine. The mixture was stirred at 25 °C for 4 hours. After the reaction was complete, the mixture was filtered, and the filter cake was washed successively with acetonitrile, methanol, and acetonitrile. The collected filter cake was concentrated under vacuum to remove the solvent, yielding 750 mg of compound 8. The loading was determined to be 254.82 μmol / g.
[0272] IV. Preparation of Ligand 1 Attached to the Solid Support
[0273] Two ligand 1 phosphoridamide monomers (compound 6) were sequentially reacted with compound 8. The phosphoridamide group reacted with the DMTlorO- group, i.e., the two compounds 6 were sequentially reacted with compound 8. Following a conventional solid-phase synthesis cycle (deprotection, coupling, oxidation to introduce thiophosphate or phosphate esters, capping), a further solid-phase synthesis cycle was performed using the corresponding 2'-modified monomer. After the reaction was complete, the entire synthesized molecule was dissociated from the solid-phase support by ammonolysis, yielding the oligonucleotide sequence linked to ligand 1. A similar approach, using ligand 2 as a linker tandemly on the positive and negative strands, is also readily available.
[0274] Preparation Example 2: siRNA Synthesis (Natural RNA / 2'-methoxy or 2'-fluorine modified RNA / RNA containing GalNac ligand)
[0275] The siRNA actually used in this embodiment contains unmodified ribonucleotides, 2'-methoxy or 2'-fluorine modified ribonucleotides, and ribonucleotides containing the corresponding GalNAc ligands. The siRNA is synthesized to a theoretical yield of 1 μmol, using a 1 μmol universal Frit solid support. All oligonucleotides were prepared on a solid-phase support with corresponding ligands on an LK-192X synthesizer. According to sequence requirements, all phosphoramidite monomers corresponding to the nucleosides were diluted 1:20 (g / mL) with anhydrous acetonitrile, and coupled twice for 3 min. Activation was performed with 0.3 M benzylthiotetrazole acetonitrile solution, followed by deprotection with 3% TCA, and capping and oxidation (or sulfidation) with CAPA / CAPB and 50 mM I2 solution (or 0.2 M PADS), respectively. After trityl-off synthesis, the solid-phase support was transferred to a 2 mL centrifuge tube, 1.2 mL of ammonia was added, and the tube was heated in a 65 °C oven for 3 h to remove the protecting group. The solution was then cooled to room temperature and concentrated under vacuum for 30 min. It was filtered through a 0.22 μm filter into a sample vial and purified using a semi-preparative reversed-phase purification system for single-strand purification. The elution gradient was 7%–30% (ACN: 100 mM TEAA) for 10 min at a flow rate of 5 mL / min. After purification, the solution was concentrated under vacuum and evaporated to dryness at room temperature. The sample was then dissolved in water, and each solution was desalted on a GEHi-Trap desalting column to elute the final oligonucleotide product. All characteristics and purity were confirmed using ESI-MS and IEX HPLC. The final product was obtained by UV concentration determination using a microplate reader, mixing equimolar amounts of the sense and antisense strands, heating at 95°C for 5 min, slowly annealing to room temperature, and finally evaporating to dryness at room temperature using a vacuum concentrator.
[0276] In this disclosure, both unmodified naked siRNA sequences and modified siRNAs were prepared according to this method, the difference being the type of phosphoramide monomer corresponding to the added nucleotide. Furthermore, depending on whether a ligand is ligated and the type of ligand used, an appropriate solid-phase carrier is employed: when no ligand is required, a general-purpose Frit solid-phase carrier is used; when ligand ligand is required, a solid-phase carrier containing the corresponding GalNAc ligand (e.g., a solid-phase carrier ligated with L96, a solid-phase carrier ligated with ligand 1) is prepared according to the art's general method for ligand-solid-phase carrier ligand connection or the method described in this disclosure.
[0277] Of course, when linking nucleotide sequences to ligands, one can either sequentially link nucleotides to a solid support linked to ligands as described above, or use a common Frit solid support to complete the sequence synthesis (without removing the protecting group and solid support) and then stepwise conjugate the corresponding GalNAc phosphoridamide monomer.
[0278] Modified sequence
[0279] The above descriptions are merely alternative embodiments, provided as examples only and not as limiting the combination of features necessary for implementing this disclosure. The headings provided are not intended to limit the various embodiments of this disclosure. Terms such as “comprising,” “including,” and “comprise” are not intended to be limiting. Furthermore, unless otherwise stated, plural forms are included when not modified by a numeral, and “or,” “or” means “and / or.” Unless otherwise defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. All disclosures and patents referenced in this disclosure are incorporated herein by reference. Various modifications and variations of the methods and compositions described in this disclosure will be apparent to one of ordinary skill in the art without departing from the scope and spirit of this disclosure. While this disclosure has been described by way of specific alternative embodiments, it should be understood that the claimed disclosure should not be unduly limited to these specific embodiments. In fact, various variations of the described modes for implementing this disclosure that are obvious to one of ordinary skill in the art are intended to be included within the scope of the appended claims.
Claims
1. A dual-target nucleic acid molecule or a pharmaceutically acceptable salt thereof for inhibiting the expression of the HBV gene and the PDL1 gene, comprising, via a linker, an HBV siRNA for inhibiting HBV gene expression and a PDL1 siRNA for inhibiting PDL1 gene expression, wherein the HBV siRNA comprises a sense strand and an antisense strand that complementarily form a double-stranded region, or is composed of a sense strand and an antisense strand that complementarily form a double-stranded region; and the PDL1 siRNA comprises a sense strand and an antisense strand that complementarily form a double-stranded region, or is composed of a sense strand and an antisense strand that complementarily form a double-stranded region; optionally, The antisense strand of the PDL1 siRNA has a nucleotide length of 18-23 nt, and the antisense strand comprises or is a sequence of 18-21 consecutive nucleotides, which are no more than 3 nucleotides distinct from the first to the 21st nucleotides starting from the 5' end of any one of the sequences SEQ ID NO: 58, 18, 24, 114, 140.
2. The dual-target nucleic acid molecule according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the antisense strand of the HBV siRNA has a nucleotide length of 18-23 nt, and the antisense strand comprises or is a sequence of 18-21 consecutive nucleotides, consisting of no more than 3 distinct nucleotides from the 1st to 21st nucleotides starting from the 5' end of any one of the sequences SEQ ID NO: 2, 4, 6, 8.
3. The dual-target nucleic acid molecule or its pharmaceutically acceptable salt according to claim 1 or 2, wherein the difference of no more than 3 nucleotides is a difference of 3 nucleotides, a difference of 2 nucleotides, a difference of 1 nucleotide, or complete sameness; And / or, 18-21 consecutive nucleotide sequences are 18, 19, 20 or 21 consecutive nucleotide sequences; And / or, the lengths of the double-stranded regions of HBV siRNA and PDL1 siRNA are independently 18-23 bp, optionally 18-21 bp, or 20-21 bp.
4. The dual-target nucleic acid molecule or its pharmaceutically acceptable salt according to any one of claims 1 to 3, wherein the antisense strand of the PDL1 siRNA comprises 20 consecutive nucleotide sequences from the 2nd to 21st nucleotides starting from the 5' end of any one of the sequences SEQ ID NO: 58, 18, 24, 114, 140 as its 2nd to 21st nucleotides, and the 1st nucleotide starting from the 5' end is any one of A, U, G, C, optionally A or U.
5. The dual-target nucleic acid molecule according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein the PDL1 siRNA sense strand and / or the PDL1 siRNA antisense strand further comprises 1-6 overhanging nucleotides at their 3' and / or 5' ends; optionally, the overhangs may be 2-6 nucleotides, 1-5 nucleotides, 2-5 nucleotides, 1-4 nucleotides, 2-4 nucleotides, 1-3 nucleotides, 2-3 nucleotides, 1-2 nucleotides, or 2 nucleotides; And / or, the HBV siRNA sense strand and / or the HBV siRNA antisense strand further include 1-6 overhanging nucleotides at their 3' and / or 5' ends; optionally, the overhangs can be 2-6 nucleotides, 1-5 nucleotides, 2-5 nucleotides, 1-4 nucleotides, 2-4 nucleotides, 1-3 nucleotides, 2-3 nucleotides, 1-2 nucleotides, or 2 nucleotides.
6. The dual-target nucleic acid molecule or its pharmaceutically acceptable salt according to any one of claims 1 to 3, wherein the PDL1 siRNA antisense strand is a polynucleotide sequence as shown in any one of SEQ ID NO: 58, 18, 24, 114, 140 or a polynucleotide sequence as shown in positions 1-21 of any one of SEQ ID NO: 58, 18, 24, 114, 140; And / or, wherein the antisense strand of HBV siRNA is a polynucleotide sequence as shown in SEQ ID NO: 2, 4, 6 or 8 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 2, 4, 6 or 8.
7. The dual-target nucleic acid molecule according to claim 6, or a pharmaceutically acceptable salt thereof, wherein: In PDL1 siRNA, The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 57, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 58 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 58; The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 17, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 18 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 18; The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 23, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 24 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 24; The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 113, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 114 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 114; Alternatively, the sense strand may be a polynucleotide sequence as shown in SEQ ID NO: 139, and the antisense strand may be a polynucleotide sequence as shown in SEQ ID NO: 140 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO:
140.
8. The dual-target nucleic acid molecule according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein: In HBV siRNA, The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 1, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 2 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 2; The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 3, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 4 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 4; The sense strand is a polynucleotide sequence as shown in SEQ ID NO: 5, and the antisense strand is a polynucleotide sequence as shown in SEQ ID NO: 6 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO: 6; Alternatively, the sense strand may be a polynucleotide sequence as shown in SEQ ID NO: 7, and the antisense strand may be a polynucleotide sequence as shown in SEQ ID NO: 8 or a polynucleotide sequence as shown in positions 1-21 of SEQ ID NO:
8.
9. The dual-target nucleic acid molecule or its pharmaceutically acceptable salt according to any one of claims 1 to 3, wherein the nucleotide lengths of the sense strand or antisense strand of the HBV siRNA and PDL1 siRNA differ by more than 2 nucleotides (e.g., 2 nucleotides, 3 nucleotides); Optionally, the antisense strand of the HBV siRNA is 23 nt long, and the antisense strand of the PDL1 siRNA is 21 nt long; Further optionally, the HBV siRNA has a positive strand length of 21 nt, and the PDL1 siRNA has a positive strand length of 21 nt; Alternatively, the extra 2 nt of the antisense strand of the HBV siRNA compared to the sense strand is located at the 3' end of the antisense strand of the HBV siRNA.
10. The dual-target nucleic acid molecule according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein, The sequence of the HBV siRNA sense strand is the nucleotide sequence shown in SEQ ID NO: 3, and the sequence of the HBV siRNA antisense strand is the nucleotide sequence shown in SEQ ID NO:
4. The sequence of the PDL1 siRNA sense strand is the nucleotide sequence shown in SEQ ID NO: 57, and the sequence of the PDL1 siRNA antisense strand is the nucleotide sequence shown in positions 1-21 of SEQ ID NO:
58.
11. The dual-target nucleic acid molecule according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein the motifs of the PDL1 siRNA positive strand and the HBV siRNA positive strand independently comprise the following modifications: 2'-fluoro modification of the 7th and 9th-12th nucleosides of the positive strand starting from the 5' end, and 2'-O-methyl modification of the remaining nucleosides of the positive strand; Optionally, the positive strand of PDL1 siRNA and the positive strand of HBV siRNA are independently modified with 2'-fluorinated nucleosides at positions 7 and 9-12 starting from the 5' end, and the remaining nucleosides in the positive strand are modified with 2'-O-methyl. Further optionally, the positive strands of PDL1 siRNA and HBV siRNA are independently composed of 2'-fluoronucleotides at positions 7 and 9-12 starting from the 5' end, and the remaining nucleotides of the positive strand are 2'-O-methylnucleotides.
12. The dual-target nucleic acid molecule according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein the motifs of the PDL1 siRNA antisense strand and the HBV siRNA antisense strand independently comprise the following modifications: 2'-fluoro modification of the nucleosides at positions 2, 14, and 16 of the antisense strand starting from the 5' end, and 2'-O-methyl modification of the remaining nucleosides of the antisense strand; Optionally, the antisense strands of PDL1 siRNA and HBV siRNA are independently modified with 2'-fluorinated nucleosides at positions 2, 14, and 16 starting from the 5' end, while the remaining nucleosides in the antisense strand are modified with 2'-O-methyl. Further optionally, the antisense strands of PDL1 siRNA and HBV siRNA have 2'-fluoronucleosides at positions 2, 14, and 16, starting from the 5' end, and 2'-O-methyl-5'-vinylphosphonate-nucleoside at position 1, starting from the 5' end, and the remaining nucleosides of the antisense strand are 2'-O-methyl modified.
13. The dual-target nucleic acid molecule of claim 11 or a pharmaceutically acceptable salt thereof, wherein the motif combination of the sense strand motif and the antisense strand motif of the PDL1 siRNA and the motif combination of the sense strand motif and the antisense strand motif of the HBV siRNA independently comprise the following modifications: 2'-fluorination of the 7th and 9th-12th nucleosides of the sense strand starting from the 5' end, and 2'-O-methylation of the remaining nucleosides of the sense strand; 2'-fluorination of the 2nd, 14th and 16th nucleosides of the antisense strand starting from the 5' end, and 2'-O-methylation of the remaining nucleosides of the antisense strand; Optionally, the 2' positions of the 7th and 9th-12th nucleosides starting from the 5' end of the sense chain are modified with 2'-fluorine, and the 2' positions of the remaining nucleosides in the sense chain are modified with 2'-O-methyl; the 2' positions of the 2nd, 14th and 16th nucleosides starting from the 5' end of the antisense chain are modified with 2'-fluorine, and the 2' positions of the remaining nucleosides in the antisense chain are modified with 2'-O-methyl. Further optionally, the nucleotides at positions 7 and 9-12 of the sense strand starting from the 5' end are 2'-fluoronucleosides, and the remaining nucleotides of the sense strand are 2'-O-methylnucleosides; the nucleotides at positions 2, 14, and 16 of the antisense strand starting from the 5' end are 2'-fluoronucleosides, the nucleotide at position 1 of the antisense strand starting from the 5' end is 2'-O-methyl-5'-vinylphosphonate-nucleoside, and the remaining nucleotides of the antisense strand are 2'-O-methyl modified.
14. The dual-target nucleic acid molecule according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein the linker links HBV siRNA and PDL1 siRNA by respectively linking to the sense strand of HBV siRNA and the sense strand of PDL1 siRNA. Optionally, the antisense strands of different siRNA molecules are not directly connected to each other, but become part of the dual-target siRNA molecule by forming a double-stranded region through complementarity with the corresponding sense strand.
15. The dual-target nucleic acid molecule or a pharmaceutically acceptable salt thereof according to claim 14, wherein the connection direction of the sense strand of HBV siRNA and the sense strand of PDL1 is as follows: (5')HBV siRNA sense strand (3')-linker-(5')PDL1 siRNA (3').
16. The dual-target nucleic acid molecule or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein the PDL1 siRNA sense strand, the PDL1 siRNA antisense strand, the HBV siRNA sense strand, and the HBV siRNA antisense strand are independently linked by phosphate thioester bonds between the first to third nucleotides starting from their 5' ends and / or between the first to third nucleotides starting from their 3' ends; Optionally, the first to third nucleotides of the naked 5' or 3' ends of the PDL1 siRNA sense strand, PDL1 siRNA antisense strand, HBV siRNA sense strand, and HBV siRNA antisense strand are linked by phosphate thioester bonds. Further optionally, the first to third nucleotides of the non-naked 5' or 3' ends of the PDL1 siRNA sense strand, the PDL1 siRNA antisense strand, the HBV siRNA sense strand, and the HBV siRNA antisense strand are linked by phosphate ester bonds. Optionally, the first to third nucleotides of the non-naked 5' end of the PDL1 siRNA positive strand and the first to third nucleotides of the non-naked 3' end of the HBV siRNA positive strand are linked by phosphate ester bonds; the first to third nucleotides of the naked 3' end of the PDL1 siRNA positive strand, the first to third nucleotides of the naked 5' end of the PDL1 siRNA negative strand, the first to third nucleotides of the naked 3' end of the PDL1 siRNA negative strand, the first to third nucleotides of the naked 5' end of the HBV siRNA positive strand, the first to third nucleotides of the naked 5' end of the HBV siRNA negative strand, and the first to third nucleotides of the naked 3' end of the HBV siRNA negative strand are linked by thiophosphate ester bonds.
17. The dual-target nucleic acid molecule or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein the HBV siRNA positive strand comprises or is a nucleotide sequence as shown in SEQ ID NO: 218, the HBV siRNA negative strand comprises or is a nucleotide sequence as shown in SEQ ID NO: 211, the PDL1 siRNA positive strand comprises or is a nucleotide sequence as shown in SEQ ID NO: 214, and the PDL1 siRNA negative strand comprises or is a nucleotide sequence as shown in SEQ ID NO:
215.
18. The dual-target nucleic acid molecule or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein the dual-target nucleic acid molecule or a pharmaceutically acceptable salt thereof is conjugated to at least one ligand; Optionally, the ligand is selected from the following: cholesterol, biotin, vitamins, galactose derivatives or analogs, lactose derivatives or analogs, N-acetylgalactosamine derivatives or analogs, and N-acetylglucosamine derivatives or analogs.
19. The dual-target nucleic acid molecule according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein the ligand is an organ-targeting ligand; optionally, it is a liver-targeting ligand; Further optionally, the liver-targeting ligand is a desialylate glycoprotein receptor (ASGPR) ligand; even further optionally, the ASGPR ligand is one or more GalNAc derivatives linked by a divalent or trivalent branched structure.
20. The dual-target nucleic acid molecule of claim 18 or 19, or a pharmaceutically acceptable salt thereof, wherein the ligand is derived from one of the following structures:
21. The dual-target nucleic acid molecule of claim 18 or a pharmaceutically acceptable salt thereof, wherein the ligand is conjugated to the 3' end and / or 5' end of the HBV siRNA sense strand, the HBV siRNA antisense strand, the PDL1 sense strand, and / or the PDL1 antisense strand in the dual-target nucleic acid molecule; Optionally, the ligand is attached as a linker between the 3' end of the HBV siRNA positive strand and the 5' end of the PDL1 siRNA positive strand; Further, optionally, the ligand is selected from the following structures: in This represents a connection to the 3' or 5' end of the positive strand of the nucleic acid molecule.
22. The dual-target nucleic acid molecule of claim 21 or a pharmaceutically acceptable salt thereof, wherein the ligand is connected to the 3' or 5' end of the sense strand via a phosphate ester bond or a thiophosphate bond; Optionally, The 5' position is linked to the 3' end of the HBV siRNA positive strand via a phosphate ester bond, and the 3' position is linked to the 5' end of the PDL1 siRNA positive strand via a phosphate ester bond.
23. The dual-target nucleic acid molecule of claim 1 or a pharmaceutically acceptable salt thereof, wherein the dual-target nucleic acid molecule is selected from the group consisting of: Wherein: Am Um, Cm, and Gm represent ribonucleotides A, U, C, and G modified with 2′-O-methyl, respectively; Af, Uf, Cf, and Gf represent ribonucleotides A, U, C, and G modified with 2′-fluorine, respectively; the 's' between adjacent nucleosides indicates that adjacent nucleosides are linked by a thiophosphate bond; the 5' position of ligand 2 is connected to the 3' end of the HBV siRNA positive strand by a phosphate bond, and the 3' position is connected to the 5' end of the PDL1 siRNA positive strand by a phosphate bond.
24. A nucleic acid delivery system comprising a dual-target nucleic acid molecule as described in any one of claims 1-23 or a pharmaceutically acceptable salt thereof.
25. The nucleic acid delivery body of claim 24, wherein the nucleic acid delivery body is a liposome, lipid nanoparticle or other polymer, endosome, exosome or vesicle.
26. A cell comprising a dual-target nucleic acid molecule or a pharmaceutically acceptable salt thereof as described in any one of claims 1-23, or comprising a nucleic acid delivery body as described in claim 24 or 25.
27. The cell of claim 26, wherein the cell is carrying or transfected with HBV virus; Optionally, the cells express HBV virus at a high level; And / or, the cells are derived from mammalian cells; optionally, they are primate cells or human cells; And / or, the cells are derived from the brain, salivary glands, heart, spleen, lungs, liver, kidneys, intestines, or tumors; optionally, the cells are liver cancer cells.
28. A pharmaceutical composition comprising: a dual-target nucleic acid molecule of any one of claims 1-23 or a pharmaceutically acceptable salt thereof, or a nucleic acid delivery body of claim 24 or 25, or cells of claim 26 or 27; and a pharmaceutically acceptable excipient.
29. Use in the preparation of a medicament by the dual-target nucleic acid molecule of any one of claims 1-23 or a pharmaceutically acceptable salt thereof, the nucleic acid delivery body of claim 24 or 25, the cell of claim 26 or 27, or the pharmaceutical composition of claim 28.
30. The use according to claim 29, wherein the drug is a drug that inhibits the expression of HBV gene and / or PDL1 gene in the subject; optionally, inhibiting the expression of HBV gene and / or PDL1 gene in the subject is used for the prevention and / or treatment of diseases mediated by HBV virus infection; further optionally, the diseases mediated by HBV virus infection are chronic hepatitis B (CHB), chronic hepatitis D (CHD), hepatogenic diabetes mellitus, cirrhosis and / or liver cancer.
31. The use according to claim 29, wherein the drug is a drug for inhibiting the expression of HBsAg, HBeAg and HBV DNA of HBV virus; optionally, the level of inhibition of the expression of HBsAg, HBeAg and HBV DNA of HBV virus is at least inhibited or reduced by 95%, 90%, 85%, 80%, 75%, 70%, 60%, 50%, 40%, 30%, 20%, or 10%.
